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the burden of obesity and the metabolic syndrome in the presence of 
increasing social stress
In today’s modern society, with sedentary lifestyle and comfort food readily available, the prevalence 
of obesity, type 2 diabetes (T2D), and cardiovascular disease (CVD) is rising tremendously. 
According to World Health Organization (WHO), in 2008 35% of adults worldwide were overweight 
and more than half a billion adults were obese (1). WHO has predicted these numbers to more 
than double by 2015. Obesity per se is a major risk factor for T2D, hypertension and CVD (2). Each 
year 2.8 million people die because of the complications induced by overweight and obesity 
(1). Clustering of risk factors for overall cardiovascular risk was first described as the metabolic 
syndrome (MetS) by Kylin in the early 1920 as constellation of hypertension, hyperglycemia 
and gout (3). Later, Raeven proposed insulin resistance as the common denominator for these 
individual cardiovascular risk factors, and over the following decades the MetS has been known 
as syndrome X, Raeven’s syndrome, and insulin resistance syndrome (4). To date, the MetS is 
considered as the most important cluster of risk factors for the development of T2D and CVD and 
subsequently increased mortality (5-8). Currently, several definitions are available for the MetS, 
of which the Third Report of the National Cholesterol Education Program’s Adult Treatment Panel 
(NCEP ATP III) is the most commonly used. To define the MetS according to the NCEP ATP III, at 
least 3 out of the following 5 criteria should be present: 1): central obesity (waist circumference 
>102 cm for men and >88 cm for women) 2): plasma high density lipoprotein-cholesterol (HDL-C) 
levels <1.03 mM (men) and <1.29 mM (women) 3): plasma triglycerides levels ≥1.7 mM 4): blood 
pressure ≥135/80 mmHg and 5): fasting glucose levels ≥6.1 mM (9). Today’s modern society is also 
characterized by chronic stress (10). Chronic stress, either social or otherwise, affects the activity 
of the hypothalamus-pituitary-adrenal (HPA) axis and facilitates changes in life style, like emotional 
“comfort” eating, and lack of sleep. Chronic stress is also associated with the development of 
central obesity, insulin resistance and MetS. Although the causes for the development of the 
MetS are most likely multi-factorial, it is plausible to assume an important role for chronic stress 
in aggravating (the development of) the MetS.
the (patho)physiology of the stress response
When an individual is exposed to a stressor, rapid changes occur within seconds to minutes through 
stimulation of both the sympathetic nervous system and the HPA axis. Perception of stress by an 
organism leads to secretion of corticotrophin releasing hormone (CRH) from the parvocellular 
compartment of the paraventricular nucleus (PVN) in the hypothalamus, which subsequently 
stimulates pituitary adrenocorticotropin (ACTH) secretion. Activation of ACTH receptors in the 
adrenal cortex leads to the synthesis and secretion of glucocorticoids (GC). GCs will then, in turn, 
down regulate the stress response by a negative feedback manner via their glucocorticoid (GR) 
and mineralocorticoid (MR) receptors in the hypothalamus, the pituitary, and the hippocampus 
(11). Secretion of GCs (i.e. cortisol in humans and corticosterone (CORT) in rodents) as a response 
to perceived stress are required to induce the necessary behavioral and metabolic adaptations for 
the individual to be able to adequately cope with the stressor (fight or flight).
In this thesis, we will focus on the metabolic adaptations. The metabolic effects of GCs 
include peripheral as well as central effects. Whereas the peripheral effects are directed towards 
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recruitment of energy availability by reduction of energy stores for gluconeogenesis (12, 13), 
the central effects of GCs are anabolic and directed towards augmentation of energy stores by 
adjusting feeding behavior and intake of palatable foods to compensate for the energy loss (14). 
As a consequence, increased cortisol exposure, like during chronic stress, will further increase 
insulin levels and food intake, facilitating the development of obesity and the MetS (15). Thus, 
short-term exposure to stress, within the right context, helps the organism to adequately cope 
with the challenge. However, if the response is not sufficient, too extreme or prolonged, it 
can have deleterious adverse effects for the organism (11). Likewise, when a stressor becomes 
chronic, a vulnerable phenotype develops: an individual that has to do concessions in its 
behavioral and metabolic adaptations. Within the central nervous system, this is characterized 
by neurodegenerative changes and cognitive impairment. The resultant metabolic mal-adaptation 
manifests as abnormal recruitment and storage of fuel, resulting in abdominal obesity, and 
osteoporosis (16).
Peripheral GC metabolism is dependent on the activity of tissue-specific 11β-hydroxysteroid 
dehydrogenase (11β-HSD) type 1 and 2, which are enzymes that convert cortisone into its active 
form cortisol and vice versa. 11β-HSD-1 is predominantly expressed in the liver, adipose tissues and 
muscle where it can amplify the intracellular concentrations of cortisol available to bind its respective 
receptors (17) and is, therefore, at least in part responsible for the unfavorable side affects, such 
as insulin resistance and adiposity that are associated with increased GC exposure (18). 11β-HSD-2 
is more prominently expressed in the kidney, where it reduces GC effects by converting cortisol 
to cortisone. However, it has been implicated that 11β-HSD-2 might also play a role in obesity as it 
has been shown to be strongly correlated with adiposity (19).















specific effects of Gcs on insulin sensitivity, lipid metabolism, 
and atherosclerosis
GCs have strong anti-inflammatory properties and are widely used as immunosuppressive agents 
but they also play a major role in the metabolism of glucose, lipids and proteins. GCs stimulate 
lipolysis, proteolysis and hepatic glucose production thereby providing substrates for oxidative 
processes (12). Overstimulation of these catabolic processes can become detrimental for the 
individual leading to metabolic derangements such as the development of central obesity (20), 
hepatic steatosis (21), dyslipidemia with increased plasma trigyceride (TG) and non-esterified fatty 
acid (NEFA) levels (22), increased protein breakdown of muscle mass (23, 24) and insulin resistance 
accompanied by glucose intolerance (25). These side affects are dependent on the dose and the 
duration of treatment (25). 
GCs inhibit pancreatic insulin secretion by reducing glucose transporter (GLUT) 2 (26, 27) 
and glucokinase G6Pase (28, 29) expression and activity, thereby decreasing glucose uptake, ATP 
synthesis and calcium influx. Activation of serum and GCs-inducible kinase (SGK) 1 by GCs can also 
augment the inward repolarizing potassium currents by upregulating Kv ion channels (30) and 
thereby limiting calcium influx and insulin secretion. Furthermore, inhibition of DAGphospholipase 
by GCs (31), which leads to decreased activation of the protein kinase (PK) C can inhibit insulin 
secretion as well as the increased expression of α
2
 adrenergic receptors that lead to reduced cyclic 
adenosine monophosphate (cAMP) levels followed by decrease in PKA activity (31, 32). GCs can also 
reduce insulin biosynthesis by reducing the adenosine triphosphate (ATP)/adenosine diphosphate 
(ADP) ratio (33, 34) and by inducing β-cell apoptosis (35). 
In skeletal muscle, GCs decrease the expression and phosphorylation of insulin receptor 
substrate (IRS)-1, phosphatidylinositol 3-kinase (PI3-K), and PKB/Akt (36-38). GCs can also interfere 
with the migration of the GLUT4 to the cell surface (39) and also reduces glycogen synthesis (40). 
Furthermore, GCs do not just induce insulin resistance in skeletal muscle, but also facilitate protein 
breakdown and reduce protein synthesis by reducing the activation of eIF4E-binding protein 1 
(4E-BP1) and ribosomal protein S6 kinase 1 (S6K1) (41), providing substrate (i.e. amino acids) (42) 
for hepatic gluconeogenesis. Indeed, GCs stimulate endogenous glucose production by the 
liver, thereby increasing insulin resistance by activating genes involved in hepatic carbohydrate 
metabolism (43) and increasing the expression of enzymes involved in gluconeogenesis, including 
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and peroxisome 
proliferator-activated receptor (PPAR)-α (44-48).
Dyslipidemia is a common side effect of increased GC exposure. GCs affect adipose tissue 
metabolism by increasing the expression and activity of hormone sensitive lipase (HSL) that 
hydrolyses TG in the adipocyte (49). Furthermore, GCs decrease lipoprotein lipase (LPL) activity in 
a site-specific manner (50-52). Consequently, fat mobilization (intracellular lipolysis) is stimulated 
increasing plasma NEFA and TG flux to the liver (53). GCs have been shown to induce intrahepatic 
lipid accumulation by decreasing FA oxidation and increasing TG synthesis (54, 55). This can lead 
to increased very low density lipoprotein (VLDL) synthesis, which further increases circulating TG.
Atherosclerosis is the most important manifestation of CVD, leading to myocardial infarction, 
congestive heart failure, stroke and peripheral artery diseases. Atherosclerosis is considered to be a 
complication of insulin resistance and dyslipidemia, which are present in the MetS and are associated 
with increased GC exposure as is seen in patients with Cushing’s syndrome (CS). Traditionally, 
it is thought that atherosclerosis develops as a consequence of cholesterol deposition in the 
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subendothelial layer after injury to the endothelium (56). Atherosclerotic lesion development can be 
triggered by increased plasma levels of low density lipoprotein (LDL), which leads to smooth muscle 
cell proliferation and can be taken up by residential macrophages to form foam cells (57). These 
processes precede the development of more complex fibrous lesions (56) in which inflammation 
is shown to play a significant role (58). 
Intriguingly, the role of GCs in the development of atherosclerosis is not yet clearly established 
in humans or in animals. GCs are known to induce vasoconstriction (59-62) and endothelial dysfunction 
(63), which can facilitate the atherosclerotic lesion development. On the other hand, GCs also have 
anti-proliferative and anti-migratory effects on vascular smooth muscle cells (64-67) that may inhibit 
the lesion development. Furthermore, it is unclear how GCs affect inflammation in the development 
of atherosclerosis, as both inhibition and stimulation of inflammation has been reported (68). 
However, these effects are at least to be considered dependent on GC concentration (69). 
Taken together, GCs acutely reduce insulin secretion and stimulate whole body lipolysis. 
However, under chronic conditions, this cycle of reduced pancreatic insulin secretion and decreased 
insulin sensitivity in skeletal muscle, liver and fat tissue results in insulin resistance and dyslipidemia, 
facilitating the development of other complications such as CVD including atherosclerosis.
cushing’s syndrome as a human model of chronic stress
CS, a rare clinical syndrome characterized by prolonged exposure to inappropriately increased 
GCs, was first described by Harvey Cushing in 1932. CS can be considered as the clinical human 
monosymptomatic equivalent for severe chronic stress. The most common cause of endogenous CS 
is an adrenocorticotropin-secreting pituitary adenoma. Other causes include ectopic ACTH secretion 
by neuroendocrine tumors or ACTH-independent cortisol overproduction by adrenal tumors or 
adrenal hyperplasia. Exogenous CS, induced by exogenous sources of GCs, such as steroid treatment 
in autoimmune diseases or prevention of graft rejection in transplantation, is very prevalent (70).
Regardless of the cause, patients with CS are exposed to supra-physiological levels of cortisol 
and display several features of chronic stress, such as depression, anxiety and cognitive impairment 
(71, 72), but they also have a phenotypical resemblance to, and fulfill the criteria for, the MetS 
(70). Indeed, CS patients have markedly increased cardiovascular morbidity and mortality (73) 
suggesting that excessive exposure to GCs is involved in the pathogenesis of MetS and central 
obesity. Furthermore, patients with MetS show increased GC metabolism (74), but the underlying 
mechanisms are only partially understood. 
Intriguingly, some of the features of MetS and certain psychopathologies in CS patients 
prevail after the removal of cortisol excess. Indeed, one year after remission, CS patients still suffer 
from impaired glucose tolerance (75) and increased insulin levels after oral glucose tolerance test 
(76). Furthermore, CS patients have an increased waist circumference after one year of remission 
(75, 76) and even after long-term remission higher visceral fat mass has been observed without 
affecting the body mass index (77). 
epidemiological and other evidence for an association between increased 
baseline activity of the Hpa axis and cardiovascular disease or obesity
The link between GCs and CVD was reported first in de 1950s, reporting elevated cortisol to be 
associated with (premature) atherosclerosis (78). Besides CS also in patients otherwise chronically 














that underwent angiography (80), increased cortisol appeared to correlate with increased intima 
media thickness (IMT). In agreement with these findings, manipulation of cortisol exposure at 
the tissue level through stimulation or abrogation of 11-β-HSD-1 activity can increase or regress 
fat accumulation in visceral depots, and well as other features of the MetS (see also subparagraph 
1.6 for references) Taken together, an increased activity of the HPA axis has been linked to the 
development of MetS (81), which has recently led to propose a pathogenic role of cortisol in the 
MetS (82). In human obesity, however, the results are rather inconclusive and not well studied. In 
obese women, urinary excretion of free cortisol is increased (83), and in men a significant correlation 
was found between salivary cortisol and both body mass index (BMI) and waist-to-hip ratio (84). 
However, it appears that cortisol secretion is increased in obese subjects primarily because of 
increased clearance and increased distribution volume, thereby resulting into secondary central 
activation of the HPA axis but with normal circulating cortisol concentrations (85, 86). Furthermore, 
the potency of ACTH to stimulate cortisol production was found to be decreased in obesity (85). In 
addition, a flattened circadian cortisol secretion rhythm in patients with T2D has been found (87). 
Thus, obesity appears to induce compensatory changes in the baseline, non-stressed, activity of 
the HPA axis, that are not unequivocally characterized by increased HPA axis activity. In addition, 
circulating cortisol levels do not always reflect the activity of the HPA axis in the central nervous 
system, nor in peripheral tissues.
animal models of (features of) the Mets in relation to the Hpa axis
Due to the similarities between the MetS and the phenotype of CS, it has been suggested that 
GCs and, in particular, increased circulating GCs might play a role in the development of MetS. A 
number of studies using different rodent models have studied the association of the activity of the 
HPA axis and various components of the MetS. The most commonly used method is high fat diet 
(HFD) feeding resulting in diet-induced obesity (DIO). One of the best-characterized models in 
this respect is the male C57Bl/6 mouse fed a HFD, where HFD induces profound insulin resistance 
and obesity (88-91). However, CORT levels, or any other parameter of the HPA axis was measured 
in only a minority of these studies. Intriguingly, the experimental mouse models of obesity and 
the MetS reveal conflicting results with respect to whether the HPA-axis is activated. Given the 
well-known time and context dependent effects of GCs, these discrepancies might be explained 
by methodological differences between the studies, including differences in rodent models. As 
the effect of HFD on HPA axis activity in the context of MetS requires further investigation, several 
studies indicate that comfort food reduces HPA axis activation and facilitates stress recovery. Indeed, 
it has been shown in rats that palatable food intake reduces the signs of stress and promotes weight 
gain, even in a chronic stress condition (92-94). These findings indicate that palatable food, such as 
HFD, has the ability, at least acutely, to reduce the stress response, facilitate recovery from stress, 
and dampen the HPA axis activity.
The effect of GCs on certain features of the MetS has also been studied in adrenalectomized 
models, where CORT concentrations are clamped to a desired level by subcutaneously implanted 
GC pellets. In combination with streptozotocin-induced destruction of pancreatic β-cells and 
subsequent exogenous insulin replacement, these studies have provided important information 
on the relative contribution of each hormone on feeding behavior, choice of food, weight gain and 
fat deposition (95). However, clamped CORT levels do not reflect normal physiology due to the 
loss of tissue sensitivity for GCs as a result of continuous high exposure. Therefore, new methods of 
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increasing GCs in the circulation are emerging, by adding them to the food (96) or drinking water 
(97), which to some degree retains the diurnal rhythm. Furthermore, 11β-HSD-1 enzyme inhibition or 
deficiency in mice results into improvement of metabolic parameters (98-100), indicating that tissue 
exposure to GCs is associated with features of MetS not just in humans but also in animal models.
As insulin resistance and obesity are readily and well studied in mouse models of DIO, 
atherosclerosis as a complication of MetS presents a challenge as wild-type mice do not develop 
atherosclerosis even in the presence of high cholesterol diet (HCD). Development of atherosclerosis 
can, however, be studied in genetically modified mouse models, which naturally over time or in 
the presence of HCD, readily develop atherosclerosis, such as the apoE-knockout (apoE-/-) mouse 
(101), the LDL receptor-knockout mouse (ldlr-/-) (102), the APOE*3-Leiden transgenic mouse (103), 
and the APOE*3-Leiden.CETP (E3L.CETP) mouse (104). To date, the effect of GCs and stress has 
mainly been investigated in other animal models such as dogs, pigs and rabbits (105). The limited 
number of studies performed in mice reveals contradictory results on whether increased GC 
exposure aggravates atherosclerosis like in CS patients, or does not influence the development 
of atherosclerosis (106, 107). 
Taken together, the relationship between the MetS and the HPA axis has been studied to 
some degree previously in animal models. However, several of these studies suffer from differences 
in methodological approach e.g. using methods that are not standardized to be stress-free or 
otherwise disrupt normal physiology greatly, which might mask true effects. Furthermore, 
differences in genetic predisposition for the development of certain features of the MetS, or 
otherwise modified (e.g. adrenalectomized) animal models will most likely affect the results. 
outline of the present thesis
In this thesis, we aimed to expand our knowledge on the pathophysiological aspects that underlie 
both the basal activity of the HPA axis during the development of obesity, and the effects of a period 
of GC excess on reversibility of metabolic parameters and atherosclerosis in mice.
In chapter 2, we performed a systematic review of studies on DIO mouse models. Although 
feeding HFD easily induces features of MetS, the rodent models reveal conflicting results with 
respect to the HPA axis activation. Therefore, we included only original mouse studies reporting 
parameters of the HPA axis after high fat feeding, and at least one basal CORT level with a proper 
control group. Studies with adrenalectomized mice, transgenic animals only, HFD for less than 
2 weeks, or other interventions besides HFD, were excluded. Subsequently, in chapter 3, we aimed 
to evaluate non-stressed diurnal HPA axis activity in mice in detail during obesity development. As 
stated in sub-paragraph 1.6, obesity-prone male C57Bl/6J mice were fed HFD or LFD for 12 weeks, 
and a detailed assessment of the activity of the HPA axis was made measuring circadian plasma 
CORT concentrations, activation of the HPA axis in the central nervous system (CRH, and GR mRNA 
expression in the hippocampus, amygdala, and hypothalamus), and activation of the HPA axis in 
peripheral tissues (11β-HSD-1 and -2 expression in adipose tissue and liver). In the second part of 
the thesis, given the observations in humans with CS, we aimed to address the potential long-term 
effects of a period of GC overexposure in mice that develop DIO or atherosclerosis. CS is associated 
with an increased incidence of MetS, and increased cardiovascular morbidity and mortality, even 
after long-term correction of GC excess. However, the causal relation between the episode of 
cortisol overexposure and long-term changes is not established and is difficult to assess in humans 














male C57Bl/6J mice, fed either a LFD or HFD, were given CORT or vehicle in the drinking water for 
4 weeks, followed by a washout period. Plasma circadian CORT, lipids, insulin, and glucose levels 
were assessed at regular intervals. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic 
clamp, and lean and body- and fat masses with dual-energy X-ray absorptiometry (DEXA). Finally, in 
chapter 5, we investigated the effects of both transient and continuous GC excess, again induced 
via CORT in the drinking water, on insulin sensitivity and atherosclerosis development in female 
APOE*3-Leiden.CETP (E3L.CETP) mice. These mice have a human-like lipoprotein metabolism 
and develop atherosclerosis upon feeding a Western-type diet. In chapter 6, a synopsis of all 
major findings is given. In addition, the data presented in this thesis are discussed in the context 
of potential implications of overexposure to stress (hormones) on the development of obesity 
and CVD in every-day-life.
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background: Hypothalamus-pituitary-adrenal-axis activity is suggested to be involved in the 
pathophysiology of the Metabolic syndrome. In diet-induced obesity mouse models, features of the 
Metabolic syndrome are induced by feeding high fat diet. However, the models reveal conflicting 
results with respect to the hypothalamus-pituitary-adrenal-axis activation. 
aim: To assess the effects of high fat feeding on the activity of the hypothalamus-pituitary-adrenal-
axis in mice.
Methods: PubMed, EMBASE, Web of Science, the Cochrane database, and Science Direct were 
electronically searched and reviewed by 2 individual researchers
study selection: We included only original mouse studies reporting parameters of the 
hypothalamus-pituitary-adrenal-axis after high fat feeding, and at least one basal corticosterone 
level with a proper control group. Studies with adrenalectomized mice, transgenic animals only, 
high fat diet for less than two weeks, or other interventions besides high fat diet, were excluded. 
results: Twenty studies were included. The hypothalamus-pituitary-adrenal-axis evalution was the 
primary research question in only 5 studies. Plasma corticosterone levels were unchanged in 40%, 
elevated in 30%, and decreased in 20% of the studies. The effects in the peripheral tissues and the 
central nervous system were also inconsistent. However, major differences were found between 
mouse strains, experimental conditions, and the content and duration of the diets.
conclusion: This systematic review demonstrates that the effects of high fat feeding on the 
basal activity of the Hypothalamus-pituitary-adrenal-axis in mice are limited and inconclusive. 
Differences in experimental conditions hamper comparisons and accentuate the need for 




















The metabolic syndrome (MetS) is a cluster of metabolic abnormalities that identifies individuals at 
high risk for cardiovascular disease (1, 2). These metabolic abnormalities include abdominal obesity, 
hypertension, dyslipidemia, and insulin resistance. The concept of the MetS is a subject of debate, 
because the pathophysiological basis of this syndrome is unclear (3). In addition, the combination of 
cardiovascular risk factors does not add to the risk related to the individual risk factors for cardiovascular 
disease (4). Nonetheless, these individual, well-recognized cardiovascular risk factors have all been 
associated with increased cardiovascular morbidity and mortality in the general population (1, 2, 4).
Several lines of evidence suggest that alterations in the activity of the hypothalamus-pituitary-
adrenal (HPA)-axis may be involved in the development of the MetS. Glucocorticoids (GC) (cortisol 
in humans and corticosterone in rodents) are secreted by the adrenals in response to a stressor, in 
order to induce the required behavioral and metabolic adaptations to be able to adequately cope 
with the stressor (fight or flight). The metabolic effects of GC include both peripheral and central 
effects. Whereas the peripheral effects are directed towards recruitment of energy availability 
by reduction of energy stores for gluconeogenesis, the central effects of glucocorticoids are 
anabolic and directed towards augmentation of energy stores by adjusting feeding behavior and 
intake of palatable foods to compensate for the energy loss. As a consequence, increased cortisol 
exposure, like during chronic stress, will further increase insulin levels and food intake, facilitating 
the development of obesity and the MetS (5, 6).
This is first exemplified by patients with Cushing’s syndrome (CS), a rare disorder caused by 
prolonged excessive exposure to glucocorticoids. Patients with CS have a phenotypical resemblance 
to and fulfill the criteria for, the MetS (7). These patients have a markedly increased cardiovascular 
morbidity and mortality (8), suggesting that excessive exposure to glucocorticoids is involved in the 
pathogenesis of MetS and central obesity. Second, patients with MetS show increased activity of the 
HPA-axis (9), but the underlying mechanisms are only partially understood (10). Third, manipulation 
of cortisol exposure at the tissue level through stimulation, or abrogation, of 11β-hydroxysteroid 
dehydrogenase type-1 (11-β-HSD-1) activity can increase, or regress, the fat accumulation in visceral 
depots, and well as other features of the MetS (11, 12).
In animal models of diet-induced obesity (DIO), common features of the MetS, like insulin 
resistance and obesity are easily induced by feeding of high fat diet (HFD). However, these 
experimental mouse models of obesity and the MetS reveal conflicting results with respect to 
whether the HPA-axis is activated. These discrepancies might be explained by methodological 
differences between the studies, including differences in rodent models. Therefore, the aim of 
the present systematic review was to critically compare the data available in mice on the effects of 
HFD feeding on basal, non-stressed activity of the HPA-axis, and to discuss possible explanations 
for the observed differences.
MetHods
search strategy 
We performed a systematic search in PubMed, EMBASE, Web of Science, the Cochrane database, 
and Science Direct, for published studies on the association between HFD feeding and activity 
of the HPA-axis. The following search strategy was used: for PubMed: (high fat diet OR high 
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lipid diet OR high fat diets OR high lipid diets OR western-type diet OR western-type diets OR 
“high-fat” OR Dietary Fats OR (diet-induced obesity)) AND (HPA-axis[tw] OR ((“Hypothalamo-
Hypophyseal System”[mesh] OR “Pituitary-Adrenal System”[mesh] OR hpa[tw]) AND axis[tw]) OR 
Hypothalamo-Pituitary-Adrenal[tw] OR Hypothalamus-pituitary-adrenal[tw] OR glucocorticoid 
OR glucocorticoids OR corticosterone) AND (mice OR mouse); for EMBASE: ((high fat diet OR 
high lipid diet OR high fat diets OR high lipid diets OR western-type diet OR western-type diets 
OR “high-fat” OR Dietary Fats OR diet-induced obesity).mp OR exp fat intake/ OR exp lipid diet/) 
AND (hypothalamus hypophysis adrenal system/ OR exp glucocorticoid/ OR corticosterone/ 
OR (HPA-axis OR ((Hypothalamo-Hypophyseal OR Pituitary-Adrenal OR hpa) AND axis) OR 
Hypothalamo-Pituitary-Adrenal OR Hypothalamus-pituitary-adrenal OR glucocorticoid* OR 
corticosterone).mp) AND (exp mouse/ OR mice.af OR mouse.af); for Web of Science: TS=((high 
fat diet OR high lipid diet OR high fat diets OR high lipid diets OR western-type diet OR western-type 
diets OR “high-fat” OR Dietary Fats OR (diet-induced obesity)) AND (HPA-axis OR ((Hypothalamo-
Hypophyseal OR Pituitary-Adrenal OR hpa) AND axis) OR Hypothalamo-Pituitary-Adrenal OR 
Hypothalamus-pituitary-adrenal OR glucocorticoid OR glucocorticoids OR corticosterone) AND 
(mice OR mouse)); for Cochrane: (high fat diet OR high lipid diet OR high fat diets OR high lipid 
diets OR western-type diet OR western-type diets OR “high-fat” OR Dietary Fats OR (diet-induced 
obesity)) AND (HPA-axis OR ((Hypothalamo-Hypophyseal OR Pituitary-Adrenal OR hpa) AND 
axis) OR Hypothalamo-Pituitary-Adrenal OR Hypothalamus-pituitary-adrenal OR glucocorticoid 
OR glucocorticoids OR corticosterone) AND (mice OR mouse); for ScienceDirect: TITLE((high fat 
diet OR high lipid diet OR high fat diets OR high lipid diets OR western-type diet OR western-type 
diets OR “high-fat” OR Dietary Fats OR (diet-induced obesity)) AND (HPA-axis OR ((Hypothalamo-
Hypophyseal OR Pituitary-Adrenal OR hpa) AND axis) OR Hypothalamo-Pituitary-Adrenal OR 
Hypothalamus-pituitary-adrenal OR glucocorticoid OR glucocorticoids OR corticosterone) AND 
(mice OR mouse)); for Academic Search Premier: ((high fat diet OR high lipid diet OR high fat diets 
OR high lipid diets OR western-type diet OR western-type diets OR “high-fat” OR Dietary Fats OR 
(diet-induced obesity)) AND (HPA-axis OR ((Hypothalamo-Hypophyseal OR Pituitary-Adrenal 
OR hpa) AND axis) OR Hypothalamo-Pituitary-Adrenal OR Hypothalamus-pituitary-adrenal OR 
glucocorticoid OR glucocorticoids OR corticosterone) AND (mice OR mouse)).
In addition, the references of relevant articles were checked for additional articles. The search 
was performed on January 27, 2011. Only original articles were included. We used the following 
exclusion criteria: adrenalectomized animals, transgenic animals only, duration of HFD of less than 
two weeks, and other interventions disabeling the interpretation of the effect of the HFD per se. 
In addition, studies were only included if 1) the effects of HFD were compared with a control group 
on standard chow or low fat diet (LFD), and 2) at least one basal (thus non-stressed) corticosterone 
sample was available for both groups.
data review
The following data were extracted from each study: mouse strain, age and/or bodyweight at baseline, 
body weight gain, housing conditions, dietary intervention (duration and content of the diet 
(percentage of calories provided as fat)), and specific parameters of HPA-axis activity: circulating 
corticosterone concentrations, 11-β-HSD-1 activity, corticotrophin-releasing hormone (CRH) 
adrenocorticotropic hormone (ACTH), and glucocorticoid receptor (GR) expression in peripheral 


















hour of evaluation (related to the circadian nadir or not), whether single or multiple time points 
were used for sampling of blood, and whether circulating corticosterone was measured only or 
combined with other central and/or peripheral parameters of HPA-axis activity. 
results 
The search strategy identified a total of 218 articles: PubMed: n=142; EMBASE: n=139, of which 26 
were unique; Web of Science: n=132, of which 39 were unique; none in the COCHRANE database, 
ScienceDirect: n=6, all unique, and 34 in Academic Search Premier, of which 5 were unique. Of 
these, 150 papers were excluded on the basis of title and abstract. The remaining 68 studies were 
retrieved for full evaluation, of which 20 studies fulfilled the in- and exclusion criteria. In only 5 
of these 20 selected studies, evaluation of selective parameters of the HPA-axis was the primary 
research question. Details of these 20 studies are summarized in Table 1. 
Mouse characteristics, housing, and diets 
The most commonly used mice were male C57Bl/6 mice. 8 studies (13-15, 23, 24, 28-30) evaluated 
the effects of HFD in C57Bl/6 mice only, and one study only in A/J mice (18). Another 6 studies 
compared C57Bl/6 mice either with A/J (19), or with transgenic mice: Leptin deficient C57Bl/6J Lep 
ob/ob (17), diabetic KKAy and ob/ob (21), 11-β-HSD-1-knockout (KO) (16, 22), and glucocorticoid 
receptor haploinsufficient GRβgeo/+ (27) mice. The remaining 5 studies used polygenic fat and lean 
mice from inbred lines (20), Balb/c mice (25), male NIH Swiss mice (26), or compared glucocorticoid 
receptor activity regulating FK506-binding protein 52 heterozygote (FKBP52+/-) male mice or 
kappa-opioid receptor knockout (KOR-KO) mice with their wild type littermates (31, 32). 
At baseline, the mean age of the mice varied from 3-19 weeks, and in one study from 6-9 
months (20). In accordance with these variations in age, body weight at baseline (when documented) 
varied from < 10 g to 30 g. 
Housing conditions were not specified in 8/20 studies. In the remaining 12 studies, mice 
were pair-housed in 3 studies, 3-4 per cage in one study, and single housed (for the entire study 
period or for the last week before sampling) in 8 studies.
Acclimation period was applied in nine studies. In 2 studies (20, 27) time was not specified. 
Another 6 studies (14, 15, 18, 21, 23, 25) had an acclimation period of one week (handling mentioned in 
only a few). Finally, one study (29) reported a 4-week acclimation period at the end of the experiment.
The duration of the diets varied between 2 and 30 weeks, and the relative contribution 
of calories derived from fat between 32% and 60% (within the HFD) and between 6.5% and 16% 
(within the LFD).
the effects of Hfd on circulating corticosterone concentrations (n=20 studies)
The evaluation of circulating corticosterone levels was limited to a single sample in 85% (17/20) of the 
studies. Blood samples were obtained between 8-11 am in 12 studies, whereas the time of sampling 
was not specified in 6 other studies. Three studies assessed diurnal variation of corticosterone 
levels, by using 2 samples (8-10 am and 7 pm) (27), or by using samples obtained every 4 h (24), 
or even every 2 h (29). 
HFD did not affect circulating corticosterone levels in 8 studies (13, 14, 18, 19, 21, 23, 25, 32) 
(all obtained a single blood sample only). 3 of these 8 studies actually reported corticosterone 
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1 Herberg L  
et al. 1975
(13)
C57Bl/6 - (NS - 4 wks - - 2 µg/dl
No effect of diet
- - -
2 Ziotopoulou M 
et al. 2000
(14)
C57Bl/6J 4wks / 20.6 g NS 43% / 
6.5%
2 wks 3.3 vs 2.3 g 8-9.30 a.m (One 
sample)
No effect of diet
(data not shown)
- - -
3 Moraes RC 
et al. 2003
(15)
C57Bl/6J 4 wks pair 36% / 3% 8 wks 11 vs 6 g Not specified (NS)
(one sample)
47 / 29 ng/ml - Various genes
(not glucose related)
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58 / 11% 18 wks 15 vs 5 g 8 a.m.
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18 / 31 nmol/l
58 / 57 nmol/l
No effect of the diet
- ↓intra-AT (visceral + 
epididymal) cort levels in 
C57BL/6J–11-β –HSD-1-KO 
vs wildtype C57BL/6J on 
LFD:
(159 ng/g; 477; and HFD: 
(404 vs 562 ng/g)
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BL6: 170 / 100 nmol/l
A/J: 100 / 60 nmol/l
- ↓ AT 11-β-HSD-1
after HFD (more in BL6 )
-
6 Bullen JW Jr 
et al. 2004
(18)
A/J 4-9 wks NS 45% / 10% 4 wks 4 to 5 g 2-3 h after lights on
(one sample, under 
CO2 narcosis )
Not different at 
1,2,3,4 wks
(data not shown)
- - PVN: CRH-R: no 
difference





23-28 g pair 65% / 63% 
cal as fat or 
starch
25 days 5 g (BL6)/
1 g (A/J)
NS
(one sample after 
anaesthesia)
BL6: 80 / 62 mmol/l
A/J: 92 / 88 nmol/l
No effect of the diet 
- - PVN: CRH: no effect 
of diet
Amygdala: CRH↑ 
in BL6; no effect 
of diet








6-9 months Single 58% / 11% 18 wks (after 
selection: 








39 / 86 nmol/l
























4 wks Body weight
44.9 vs 44.4g
50.4 vs 48.7 




0.23 / 0.17 µM
0.92 / 1.30 µM
BL6: (LFD): 0.08 µM
No effect of the diet
- -Liver cort
3.0 -5.1 and 6.2- 8.1−fold, 
and 11−DHC 3.4-3.6 and 
6.7-8.2−fold ↑ in KKAy and 
ob/ob vs WT)
- Mesenteric AT cort 2.7- 
4.2−fold ↑, and 11-DHC 
2-4−fold ↑ in ob/ob vs in 
KKAy mice
No C57/BL6 (nM/Kg)
- Epididymal AT cort 
3.0- 6.2−fold ↑,and 11DHC 
1.8- 2.0−fold ↑ in ob/ob vs 
KKAy mice, WT not shown
-
table legends: WT: wild type; HFD: high Fat Diet; LFD: low Fat diet; Chol: cholesterol; NS: not specified; 
Cort: corticosterone; PVN: paraventricular nucleus of the hypothalamus; 11-β-HSD-1: 11 beta hydroxysteroid 
dehydrogenase type 1; CRH: corticotrophin-releasing hormone ACTH: adrenocorticotropic hormone; 
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pair 58% / 11% 2 or 18 wks 15 vs 5 g Between 8-10
(one sample)
2 wk: 40 / 130 nmol/l
18 wk: 170 (HFD) 
nmol/l
- - -PVN: 2 wks: ↑11 




no change in 
11-β-HSD-1: (2 nor 
18 wks)
11 Luque RM et al. 
2006
(23)
C57Bl/6J 4 wks single 60% / 10% 16 wks 25 vs 15 g Between 8-11
(one sample)
0.9 / 0.7 ng/ml
No effect of the diet
- - -
12 Kohsaka A et al. 
2007
(24)
C57Bl/6J 6 wks NS 45% / 16% 6 wks 8 vs 4 g Every 4 h 2-15 / 3-20 µg/dl - - -
13 Chen H et al. 
2007
(25)
Balb/c 5 wks NS 32% / 12% 7 wks 8 vs 5 g NS
(one sample after 
anaesthia)
198 / 221 ng/ml 
No effect of the diet
- - -
14 McClean PL 
et al. 2007
(26)
NIH Swiss 8 wks single 45% / 10% 160 days Final mean 
body weight 
55 vs 38 g
NS
(one sample)








≤ 10 g Standard; 
single for 
sampling
58% / 11% 22 wks 40 vs 20 g Diurnal
8-10 h, 19 h
50-100 (m-e) /
25-75 (m-e) nmol/l










16 Liu Y et al. 2008
(28) 
C57Bl/6 6 wks NS 58% / 11% 30 wks Final mean 
body weight 
56 vs 32 g
9-10 am
(one sample)
36 / 23 ng/ml - - -
17 Veniant MM 
et al. 2009
(29)
C57Bl/6 3 wks (HFD)
16 wks (chow)
Single for 4 
last weeks
60% / chow 13 wks - Diurnal
Every 2 h from 4.30-
20.30 h
26 / 42 (nadir)
526 / 526 ng/ml 
(peak)





18 Matsumoto S 
et al. 2009
(30)
C57Bl/6J 4 wks NS 2% chol vs 
normal diet
2 wks 7 vs 7 g 8 a.m.
(one sample)
Appox 50 / 30 ng/ml - - POMC mRNA ↑ 
after high Chol diet 
(circ ACTH also ↑)











260 / 180 ng/ml
190 / 225 ng/ml No 
effect of the diet 
for WT
- - -





7-8 wks 3-4 per 
cage
45% / 5% 16 wks 15 vs 4.6 g 11 a.m. 76 / 114 ng/ml - - -
table legends: WT: wild type; HFD: high Fat Diet; LFD: low Fat diet; Chol: cholesterol; NS: not specified; 
Cort: corticosterone; PVN: paraventricular nucleus of the hypothalamus; 11-β-HSD-1: 11 beta hydroxysteroid 
dehydrogenase type 1; CRH: corticotrophin-releasing hormone ACTH: adrenocorticotropic hormone; 
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concentrations in conscious conditions, which varied widely (more than 200 fold): from 
0.7-0.9 ng/ml (23), 27.7 ng/ml (21), to 76 ng/ml (32) in the morning nadir. 3 out of the 8 studies 
reported corticosterone concentrations under anesthesia (18, 19, 25) and even in the millimolar 
range (19). 2 remaining studies did not specify the time of the sampling (13) or did not report the 
corticosterone concentrations (14).
HFD increased corticosterone concentrations in 6 other studies (15, 17, 26, 27, 28, 30) after 2, 
8, 18, 23, and 30 weeks of diet. In C57Bl/6 mice the corticosterone concentrations varied from 47 
vs 29 ng/ml, 59 vs 35 ng/ml, 36 vs 23 ng/ml, to 50 vs 30 ng/ml (15, 17, 28, 30) and 35 vs 21 ng/ml (in 
A/J mice) (17). 3 of these studies did not specify the time of sampling (15, 26, 28) and one did not 
specify the strain (30).
HFD decreased corticosterone concentrations in 4 other studies (22, 24, 29, 31), 2 of which 
sampled corticosterone more than once daily. The first study sampled plasma corticosterone 
levels every 4 h and found that HFD decreased both nadir (20 vs 30 ng/ml) and peak (150 vs 
200 ng/ml) corticosterone concentrations after 6 weeks of the diet (24). In contrast, Véniant et al. 
(29) found that HFD decreased the nadir (26 vs 42 ng/ml) corticosterone concentrations evaluated 
every 2 h whereas HFD did not affect peak corticosterone (526 ng/ml) after 13 weeks of the diet. 
Finally, one study documented that HFD decreased corticosterone levels at 2 weeks but increased 
corticosterone concentrations after 18 weeks of the diet (22). The remaining study showed a 
decrease in the morning nadir, but the sample was obtained under anesthesia.
The remaining one study reported an effect of genotype or breeding on circulating 
corticosterone concentrations after HFD: MF1-11-β-HSD-1-KO and C57Bl/6J-11-β-HSD-1-KO mice had 
higher circulating corticosterone concentrations than their wild type littermates (16). In addition, 
other studies reported the effect of genotype or breeding on cortcosterone concentrations: 
C57Bl/6J showed higher corticosterone concentrations than A/J mice (17) and polygenic lean mice 
from inbred lines had higher corticosterone concentrations after 18 weeks of HFD than their fat 
littermates (86 vs 39 nmol/l, respectively) (20).
the effects of Hfd on peripheral tissue specific 11-β-Hsd-1 expression 
(n=6 studies)
HFD increased corticosterone levels in visceral and epididymal fat after 18 weeks on HFD: 562 
vs 477 ng/g in C57Bl/6J mice (16), and this effect of HFD was even more pronounced in C57Bl/6 
J–11-β-HSD-1-KO mice (477 vs 159 ng/g, HFD vs control diet, respectively). However, another 
study (17) reported that HFD decreased 11-β-HSD-1 expression in adipose tissue, which was more 
pronounced in C57Bl/6 than in A/J mice, whereas HFD increased hepatic 11-β-HSD-1 expression 
(20). A fourth study found that HFD increased hepatic, epididymal, and visceral corticosterone 
levels in KKAy and ob/ob mice (21). The remaining 3 studies found effects on various genes (15), 
of genotype (C57Bl/6 vs GRβgeo +/+ (27)), and influence of time on the effectiveness of 11 β-HSD 
inhibition (29).
the effects of Hfd on the central nervous system (n=5 studies)
Within the paraventricular nucleus of the hypothalamus (PVN), HFD did not affect CRH expression 
(2 studies: ref 18, 19), POMC expression (1 study: ref 27), or GR expression (1 study: ref 20). One 
study (22) found that HFD increased 11-β-HSD-1 expression transiently in the arcuate nucleus of 


















affect CRH expression in the amygdala in C57Bl/6 or A/J mice (19). Within the hippocampus, HFD 
did not alter GR expression (20) or 11-β-HSD-1 expression (22).
discussion
This systematic review demonstrates that data on the effects of HFD in mice on the basal activity 
of the HPA-axis are limited, and inconclusive. Circulating corticosterone concentrations in a total 
of only 20 studies were found to be increased, unchanged, or decreased. The relative energy 
contribution of fat in the HFD varied between 36-58%, 32-65% and 58-60%, respectively. In addition, 
data on the effects of HFD on 11-β-HSD-1 expression in the peripheral tissues and CRH and GR 
expression in the central nervous system (only 5 studies) were inconsistent. However, differences 
in mouse strains, housing and sampling conditions, and in the content and duration of the diets 
preclude simple comparisons of the effects of HFD on the activity of the HPA-axis, and accentuate 
the need for standardized evaluations to discern the effects of fat and diet-induced obesity on 
HPA-axis and the metabolic syndrome.
From an evolutionary point of view, the regulation of energy balance is integrated in the 
neurobiology of stress, i.e. into the regulation of the allostatic responses to environmental demands. 
Glucocorticoids are the main mediators of the stress response (33) and regulate fuel homeostasis 
by increasing feeding behavior when food becomes available (34). Within the hypothalamus, a 
rapid fine-tuned hormonal cross-talk exists between glucocorticoids and leptin, acting via leptin 
blockade of the glucocorticoid-induced, endocannabinoid-mediated suppression of excitation of 
the CRH expressing neurons. This provides a nutritional state-sensitive mechanism that integrates 
the neuroendocrine regulation of energy homeostasis and the stress response (35). HFD induced 
obesity is not only accompanied by higher leptin and insulin levels (15, 24) but also by altered 
diurnal patterns of leptin and insulin (24), which affect hypothalamic CRH suppression of HPA-axis.
Different housing conditions also affect the activity of the HPA-axis and might be considered 
as chronic social stress, which in turn influences the propensity to become obese. This is best 
illustrated by a recently proposed model of psychosocial stress in rats (a resident–intruder paradigm) 
linking allostatic load to metabolic disorders (36), and confirmed in mice (37). This model states that 
MetS and obesity can develop in presence of a HFD only when an environmental threat prevents 
active coping (fight/flight), but permits only a passive strategy. These experiments demonstrated 
that when both dominant and subordinate rodents were faced with a threatening situation, a similar 
overactive HPA-axis and hyperphagia was seen in both. However, dominants responded with an 
active coping style associated with sympathetic over activity in metabolic tissues that limited the 
development of obesity despite overfeeding, whereas subordinates responded with a passive 
helplessness strategy and, particularly when faced with a HFD, developed weight gain and obesity. 
Thus, the effects of stress and HFD appear to be less detrimental dependent on the ability of the 
individual to adequately cope with the stress, as a result of genetic predisposition, and/or social 
factors. These data accentuate the important role of psychosocial stress in modulating the individual 
vulnerability to weight gain, provided that the individual is fed an “unhealthy” high-fat diet. 
When evaluating the impact of high fat feeding on adrenal axis function in mice, therefore, 
an appropriate study design is a prerequisite, and at least the following factors should be taken 
into account: first, the choice for a mouse strain that, upon high fat feeding, has previously shown 
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to provide a validated model for the development of specific features of the MetS, like obesity and 
insulin resistance. Second, standardization of content and duration of the diet. Third, standardization 
of acclimation period, housing conditions, and method for stress free sampling, and finally: the time 
of sampling. The relative contributions of each of these different factors can only be compared when 
study designs control for all these factors, except the one that is considered to be the intervention.
In conclusion, the effects of HFD on basal activity of the HPA-axis and its contribution in the 
propensity to become obese and develop other manifestations of the metabolic syndrome on a 
HFD are still unclear, but are at least time and context dependent. Proper standardization of these 
factors is critical in the evaluation of the role of the HPA-axis in further studies involving rodent 
models of the MetS. 
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Alterations of the hypothalamus-pituitary-adrenal (HPA) axis activity have been linked to the 
development of metabolic syndrome (MetS). Common features of the MetS, like insulin resistance 
and obesity, are reproducibly induced by high fat diet (HFD) in animal models of diet-induced 
obesity (DIO). These models, hampered by methodological differences, reveal conflicting results 
with respect to HPA axis activation.
This study was aimed to evaluate in detail non-stressed diurnal HPA axis activity in mice 
during obesity development. Male C57Bl/6J mice were fed high or low fat diet for 12 weeks. HPA 
axis activity was evaluated by plasma corticosterone concentrations (at 0700, 1200, and 1800 h), 
corticotropin-releasing hormone (CRH) and glucocorticoid receptor (GR) mRNA expression in the 
hippocampus, amygdala, and hypothalamus, and 11β-hydroxysteroid dehydrogenase type-1 and -2 
(11β-HSD-1 and -2) expression in adipose tissue and liver. Within one week, HFD induced obesity and 
decreased corticosterone levels at 1200 and 1800 h, which persisted throughout the experiment. 
12 weeks of HFD decreased CRH mRNA in the PVN and amygdala and GR mRNA in the PVN at 
0900 h. At 1800 h, CRH mRNA expression increased in PVN and amygdala, and GR mRNA increased 
in the CA1 region. 11β-HSD-1 expressions decreased in gonadal, visceral and subcutaneous adipose 
tissue at 0900 h and at 1800 h, whereas hepatic 11β-HSD-1 expression increased at 1800 h whereas 
11β-HSD-2 expression was unaffected. HFD induces complex changes in the diurnal regulation of 
the different components of the HPA axis. These changes are not unequivocally characterized by 



















Glucocorticoids (GC) (cortisol in humans and corticosterone in rodents) are secreted by the 
adrenals in response to stimulation of the hypothalamus-pituitary-adrenal (HPA) axis by a stressor, 
and induce behavioral and metabolic adaptations enabling the host to adequately coping with the 
stressor (fight or flight). Increased activity of the HPA axis has been linked to the development of the 
Metabolic Syndrome (MetS) (1). The metabolic effects of GC are directed both towards recruitment 
of energy stores for gluconeogenesis (peripheral effects), and towards augmentation of energy 
stores by adjusting feeding behavior and intake of palatable foods to compensate for the energy 
loss (central effects). Increased GC exposure will increase food intake and insulin levels, facilitating 
the development of obesity and the MetS (2, 3). In accordance, patients with Cushing’s syndrome 
(CS), which is caused by prolonged excessive exposure to GC, exhibit many features of the MetS 
(4) associated with increased cardiovascular morbidity and mortality (5). Finally, manipulation of 
cortisol exposure at the tissue level in mice, through stimulation or abrogation of 11β-hydroxysteroid 
dehydrogenase type-1 and -2 (11-β-HSD-1 and 11-β-HSD-2) activity can increase, or regress, visceral 
fat accumulation, as well as other features of the MetS (6, 7).
Nonetheless, it is still controversial how the development of the MetS and its complications 
affect the activity of the HPA axis. Common features of the MetS, like insulin resistance and obesity, 
are reproducibly induced in mouse models of diet-induced obesity (DIO) by feeding of high fat 
diet (HFD), but the effects on the activity of the HPA axis have been evaluated in only a minority 
of these studies, and their results are conflicting. Many factors, like differences in mouse strains, 
housing and sampling conditions, but also the content and duration of the diets affect the activity 
of the HPA axis and preclude simple comparisons after induction of DIO. In addition, the evaluation 
of the HPA axis in most studies was restricted to a single measurement of plasma corticosterone 
levels, which was combined with either 11-β-HSD-1 enzyme activity in peripheral tissues or in the 
central nervous system in only a few of these studies (8).
Therefore, the aim of the present study was to evaluate the effects of HFD in mice in detail 
on basal, non-stressed activity of the HPA axis, using standardized evaluations that control for 
housing and sampling conditions. For these studies, we used C57Bl/6J mice that develop obesity 
and insulin resistance upon HFD (9-12).
Material and MetHods
Mouse strain, housing, and diets
In the current study we used male C57Bl/6J mice (Charles River, Maastricht, The Netherlands), which 
develop, obesity and insulin resistance, specific features of the MetS (9-12). Twelve-week-old mice 
(n=36) were single housed in a separate room from other experimental animals in the facility to 
minimize environmental stressors, and maintained on a 12 h:12 h light-dark cycle (lights on 7 a.m.) 
at controlled room temperature (21-22°C) and fed ad libitum with free access to drinking water. 
Mice were weight-matched and randomly assigned to the following diets for 12 weeks: high fat 
diet (45 energy % lard fat, D12451, Research Diet Services, Inc, New Brunswick, US) (HFD) (n=18) or 
low fat diet (10 energy % lard fat, D12451B, Research Diet Services, Inc, New Brunswick, US) (LFD) 
(n=18). All mice were fed LFD for three weeks before starting the HFD. 
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All animal experiments were performed in accordance with the regulations of Dutch law 
on animal welfare and the institutional ethics committee for animal procedures from the Leiden 
University Medical Center approved the protocol.
sampling of corticosterone
Mice on LFD (n=18) and HFD (n=18) were divided into two groups of 9 mice, and blood for 
measurement of plasma corticosterone levels was sampled in week 1, 5, and 9 (first group), or 
at week 3, 7 and 11 (second group). Blood samples were collected during the first light hour at 
0700 h, at 1200 h, and during the last light hour at 1800 h. To establish that the peak plasma 
corticosterone peak had not ‘shifted’ toward the dark hours of the light/dark cycle, at week 11, 
plasma corticosterone was measured at 1900 h, 2000 h and 2100 h during the dark phase in red 
light conditions. All corticosterone samples were obtained within 90 seconds from disturbing the 
cage, via tail incision, allowing the mouse to move freely on top of the home cage (13). Plasma insulin 
was measured after a 4-hour fast in the same weeks as corticosterone. Plasma leptin levels were 
determined from the trunk blood after decapitation. After 12 weeks, the mice were decapitated 
within 90 seconds from disturbing the cage, either in the morning (0900-1000 h) or during the last 
light hour (1800-1900 h). After decapitation, the trunk blood was collected, the brain was harvested 
and snap frozen in isopentane and stored at –80°C. Liver, muscle, gonadal, abdominal visceral and 
subcutaneous fat pads were dissected, snap-frozen in liquid nitrogen and stored at –80°C.
plasma hormone measurements
Plasma corticosterone levels were determined by radioimmunoassay (MP Biomedicals LLC, 
Orangeburg, NY; intra-assay variation 7.3%, inter-assay variation 6.9%,). 
Insulin and leptin were measured with ELISA (Crystal Chem Inc., Downers Grove, IL, USA; 
intra-assay precision coefficient of variation ((CV)≤10% and inter-assay precision CV≤10% for both 
kits). All measurements were assayed according to the manufacturer’s instructions.
evaluation of Hp- axis activity in the central nervous system (in situ 
hybridization)
Brain sections of 16 µm of the paraventricular nucleus (PVN) (Bregma -0.70mm), amygdale (Bregma 
-0.70 mm) and hippocampus (Bregma -1.70 mm) were cut according to the brain atlas of Paxinos 
and Franklin 2001 (14) on a cryostat and mounted on polysine microscope slides (Menzel-Gläzer, 
Braunschweig, Germany) and stored in -80°C until further use. The hybridization was performed 
as described previously by Meijer et al. 1997 (15) with minor adjustments. Briefly, sections were 
fixed in 4% paraformaldehyde, further permeabilized by proteinase K treatment, acetylated twice 
with 0.25% acetic anhydride in 0.1 M triethanolamine and dehydrated in a graded ethanol series.
Riboprobes were generated from linearized constructs containing the respective cDNAs in 
pBluescript. A 500-bp SalI–HindIII fragment of exon 2 of the mouse gene was used for GR (16). The 
cRNA from CRH was transcribed from a 1-kb cDNA insert in pGEM 4 containing full-length coding 
region of rat CRH (17). 35S-UTP labeled antisense probes were generated using the appropriate 
polymerase using a standard protocol.
A hybridization mix was prepared containing 60% deionized formamide, 10% Dextran SO
4
, 
2xSSC, 0.1 mg/ml yeast tRNA, 0.1 mg/ml sssDNA, 10 mM dithiothreitol, 0.05 M PBS. All radiolabeled 
probes were diluted to 16.7x106 cpm/ml. Of these mixtures 120 µl was applied to each slide and then 


















The next day, the cover slips were removed carefully and sections were washed in 2xSSC for 10 min 
at room temperature. After washing, sections were treated with RNAse A (2 mg/100 ml in 0.5 mol/l 
NaCl, 0.1 mol/l Tris, pH 7.5) at 37°C for 10 min and subsequently washed at 55°C in 2xSSC for 10 min, 
1xSSC for 10 min, 0.1xSSC for 2x30 min and, finally, at room temperature in 0.1xSSC for 5 min. Sections 
were dehydrated in an ethanol series (70%, 80%, 96% and 100% ethanol) and dried on air. Signal was 
visualized with exposure of Kodak Biomax MR films, scanned and quantified by using Image J software 
(National Institutes of Health) and related to standard curves of 14C (RPA 504 microscales; Amersham, 
Buckinghamshire, UK). Two sections per mouse per brain area were quantified. For CRH mRNA in PVN 
and amygdala and for GR mRNA in the PVN, the values represent a sum of the two areas measured. 
For GR mRNA in the hippocampus, the values represent the average of the two measurements. 
11β-Hsd-1 and 11β-Hsd-2 expression analysis in liver and adipose tissue 
Total RNA was extracted from liver and adipose tissues using the Nucleospin RNA II kit (Macherey 
Nagel, Düren, Germany) according to manufacturer’s instructions. RNA quality was examined with 
lab-on-a-chip technology using Experion Std Sens analysis kit (Biorad, Hercules, CA). Total RNA was 
reverse-transcribed with iScript cDNA synthesis kit (Bio-Rad) and the obtained cDNA was purified 
with Nucleospin Extract II kit (Macherey-Nagel). Real-time PCR for 11β-HSD-1 (forward primer: 
CAGCAAAGGGATTGGAAGAG; reverse primer: CTTTCCCGCCTTGACAATAA) and 11β-HSD-2 (forward 
primer: TTTGGTGCACTTGAGCTGAC; reverse primer: AGCCGAATGTGTCCATAAGC) were carried out on 
the IQ5 PCR machine (Biorad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). mRNA 
levels were normalized to mRNA levels of cyclophilin (forward primer: CAAATGCTGGACCAAACACAA; 
reverse primer: GCCATCCAGCCATTCAGTCT) and hypoxanthine guanine phosphoribosyl transferase 
(forward primer: TTGCTCGAGATGTCATGAAGGA reverse primer: AGCAGGTCAGCAAAGAACTTATAG).
statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using Mann-Whitney test 
for non-parametric data, with GraphPad Prism, version 5.01. (GraphPad Software, Inc.La Jolla, CA), 
P<0.05 was considered as statistically significant.
results
High fat diet increases plasma insulin and leptin levels and body weight 
without affecting thymus weight
As anticipated, HFD feeding resulted in a greater increase in body weight as compared to LFD, which 
already reached significance within 1 week, and this difference remained significant throughout 
the experiment (Fig. 1A). HFD did not affect the thymus weight (Fig. 1B). HFD increased plasma 
insulin concentrations already within one week (Fig. 1C), which remained significantly increased 
throughout the experiment. Plasma leptin levels were significantly increased after 12 weeks of HFD 
both at 0900 h and 1800 h Fig 1D). 
High fat diet decreases diurnal peak plasma corticosterone levels both 
acutely and in the long term
A diurnal corticosterone rhythm was observed in all animals, with a nadir in the morning (0700 h) and 




and hypoxanthine guanine phosphoribosyl transferase (forward primer: 




Data are presented as means ± SD. Statistical differences were calculated using Mann-
Whitney test for non-parametric data, with GraphPad Prism, version 5.01. (GraphPad 
Software, Inc.La Jolla, CA), P<0.05 was considered as statistically significant. 
  
RESULTS 
High fat diet increases plasma insulin and leptin levels and body weight without 
affecting thymus weight 
As anticipated, HFD feeding resulted in a greater increase in body weight as compared to 
LFD, which already reached significance within 1 week, and this difference remained 
significant throughout the experiment (Fig. 1A). HFD did not affect the thymus weight 
(Fig. 1B). HFD increased plasma insulin concentrations already within one week (Fig. 
1C), which remained significantly increased throughout the experiment. Plasma leptin 
levels were significantly increased after 12 weeks of HFD both at 0900 h and 1800 h Fig 
1D).  
Figure 1. Effect of diet on 
male C57Bl/6J mice fed a 
low fat diet (open circles and 
bars) or high fat diet (closed 
circles and bars) on body 
weight  (A), thymus weight 
at week 12 (B), plasma 
insulin concentrations at 
week 1 (C) and plasma 
leptin levels at week 12 (D), 

























































































































figure 1. Effect of diet on male C57Bl/6J mice fed a low fat diet (open circles and bars) or high 
fat diet (closed circles and bars) on body weight (A), thymus weight at week 12 (B), plasma 
insulin concentrations at week 1 (C) and plasma leptin levels at week 12 (D), Mann-Whitney test, 
*P<0.01, **P<0.001, ***P<0.0001.
figure 2. Effect of high fat diet on circadian plasma corticosterone. Male C57Bl/6J mice were 
fed a LFD (open bars) or HFD (closed bars), and plasma corticosterone was determined in the 
morning (0700), at noon (1200) or at the evening peak (1800) after 1 week (A), 7 weeks (B). At 
11 weeks (C) corticosterone was determined at 1900, 2000 and 2100 (n=6 per time point), and 






High fat diet decreases diurnal peak plasma corticosterone levels both acutely and 
in the long term 
A diurnal corticosterone rhythm was observed in ll animals, with a nadir in the morning 
(070  h) and with peak values during the last light hour before the dark phase (1800 h). 
HFD decreased plasma corticosterone levels within one week by 44% at 1200 h, and by 
52% at 1800 h in the evening (Fig. 2A). This decrease in evening peak corticosterone 
levels persisted throughout the experiment at weeks 7 and 12 (Fig. 2B and D). 
Furthermore, peak corticosterone levels were not ‘shifted’ toward the dark hours of the 
light/dark cycle but declined from the 1800 to 1900 h time points in both LFD and HFD 
groups. The suppression of plasma corticosterone levels was also evident in HFD group 
during the egin ing of t e dark phase (at 1900 h, 2000 h) at week 11 when compared to 
the LFD group (Fig. 2C). 
 
Figure 2. Effect of high fat diet on circadian plasma corticosterone. Male C57Bl/6J mice were fed a LFD 
(open bars) or HFD (closed bars), and plasma corticosterone was determined in the morning (0700), at 
noon (1200) or at the evening peak (1800) after 1 week (A), 7 weeks  (B). At 11 weeks (C) corticosterone 
was determined at 1900, 2000 and 2100 (n=6 per time point), and at 12 weeks (D) at 0900 and 1800. Mann-
Whitney test, *P<0.05, **P<0.01. 
 
High fat diet i duces changes in mRNA expression of CRH and GR in the brain  
HFD sig ificantly decreased CRH mRNA expression in the PVN and amygdala at 0900 h 
in the morning (Fig. 3A and B). Moreover, HFD decreased GR mRNA in the PVN at 
0900 h in the morning basal period (Fig. 3C). HFD increased CRH mRNA expression at 
1800 h in the evening in both PVN and amygdale (Fig. 3A and B). Furthermore, HFD 










































































High fat diet decreases diurnal peak plasma corticosterone levels both acutely and 
in the long term 
A diurnal corticosterone rhythm was observed in all animals, with a nadir in the morning 
(0700 h) and with peak values during the last light hour before the dark phase (1800 h). 
HFD decreased plasma corticosterone levels within one week by 44% at 1200 h, and by 
52% at 1800 h in the evening (Fig. 2A). This decrease in evening peak corticosterone 
levels persisted throughout the experiment at weeks 7 and 12 (Fig. 2B and D). 
Furthermore, peak corticosterone levels were not ‘shifted’ toward the dark hours of the 
light/dark cycle but declined from the 1800 to 1900 h time points in both LFD and HFD 
groups. The suppression of plasma corticosterone levels was also evident in HFD group 
during the beginning of the dark phase (at 19  h, 2000 h) at week 11 when compared to 
the LFD group (Fig. 2C). 
 
Figure 2. Effect of high fat diet on circadian plasma corticosterone. Male C57Bl/6J mice were fed a LFD 
(open bars) or HFD (closed bars), and plasma corticosterone was determined in the morning (0700), at 
noon (1200) or at the evening peak (1800) after 1 week (A), 7 weeks  (B) At 11 weeks (C) c ticosterone 
was determined at 1900, 2000 and 2100 (n=6 per time point), and at 12 weeks (D) at 0900 and 1800. Mann-
Whitney test, *P<0.05, **P<0.01. 
 
High fat diet induces changes in mRNA expression of CRH and GR in the brain  
HFD significantly decreased CRH mRNA expression in the PVN and amygdala at 0900 h 
in the morning (Fig. 3A and B). Moreover, HFD decreased GR mRNA in the PVN at 
0900 h in the morning basal period (Fig. 3C). HFD increased CRH mRNA expression at 
1800 h in the evening in both PVN and amygdale (Fig. 3A and B). Furthermore, HFD 






















































































corticosterone levels within one week by 44% at 1200 h, and by 52% at 1800 h in the evening (Fig. 2A). 
This decrease in evening peak corticosterone levels persisted throughout the experiment at weeks 
7 and 12 (Fig. 2B and D). Furthermore, peak corticosterone levels were not ‘shifted’ toward the dark 
hours of the light/dark cycle but declined from the 1800 to 1900 h time points in both LFD and HFD 
groups. The suppression of plasma corticosterone levels was also evident in HFD group during the 
beginning of the dark phase (at 1900 h, 2000 h) at week 11 when compared to the LFD group (Fig. 2C).
High fat diet induces changes in mrna expression of crH and Gr in the brain 
HFD significantly decreased CRH mRNA expression in the PVN and amygdala at 0900 h in the 
morning (Fig. 3A and B). Moreover, HFD decreased GR mRNA in the PVN at 0900 h in the morning 
basal period (Fig. 3C). HFD increased CRH mRNA expression at 1800 h in the evening in both PVN 
and amygdale (Fig. 3A and B). Furthermore, HFD increased GR mRNA in the evening in the CA1 
region (Fig. 3D), but not in the other regions (CA3 and dentate gyrus (DG) of the hippocampus 
(Fig. 3E and G).
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increased GR mRNA in the evening in the CA1 region (Fig. 3D), but not in the other 
regions (CA3 and dentate gyrus (DG) of the hippocampus (Fig. 3E and G). 
  
 
Figure 3. Effect of high fat diet on 
mRNA expression of CRH and GR in 
the hypothalamus and hippocampus. 
Male C57Bl/6J mice were fed a LFD 
(open bars) or HFD (closed bars) for 12 
weeks, and mRNA expression was 
determined: CRH in the PVN (A) and 
amygdale (B), and GR in the PVN (C), 
CA1 (D), CA3 (E) and DG (F) region 
of the hippocampus in the morning 
(7.00) and evening (18.00) (black bars). 










High fat diet feeding induces opposite changes in 11β-HSD-1 mRNA expression in 
adipose tissue and liver, whereas 11β-HSD-2 mRNA expression remains unaffected 
HFD decreased 11β-HSD-1 expression in gonadal, visceral and subcutaneous adipose 
tissues both in the morning by 65%, 37% and 66%, respectively (Fig. 4B, C and D), and 
in the evening by 62%, 47% and 67%, respectively, whereas no changes were observed in 
11β-HSD-2 expression in the same tissues at both time points (Fig 4B, C and D). In 
contrast, in the liver, HFD increased 11β-HSD-1 expression at 1800 h by +23% whereas 









































































































































































































figure 3. Effect of high fat diet on mRNA expression of CRH and GR in the hypothalamus and 
hippocampus. Male C57Bl/6J mice were fed a LFD (open bars) or HFD (closed bars) for 12 weeks, 
and mRNA expression was determined: CRH in the PVN (A) and amygdale (B), and GR in the PVN 
(C), CA1 (D), CA3 (E) and DG (F) region of the hippocampus in the morning (7.00) and evening 
(18.00) (black bars). Mann-Whitney test, *P≤0.05, **P<0.01, ***P<0.001
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High fat diet feeding induces opposite changes in 11β-Hsd-1 mrna 
expression in adipose tissue and liver, whereas 11β-Hsd-2 mrna expression 
remains unaffected
HFD decreased 11β-HSD-1 expression in gonadal, visceral and subcutaneous adipose tissues both 
in the morning by 65%, 37% and 66%, respectively (Fig. 4B, C and D), and in the evening by 62%, 
47% and 67%, respectively, whereas no changes were observed in 11β-HSD-2 expression in the 
same tissues at both time points (Fig 4B, C and D). In contrast, in the liver, HFD increased 11β-HSD-1 
expression at 1800 h by +23% whereas 11β-HSD-2 expression was not affected (Fig. 4A).
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Figure 4. Effect of high fat 
diet on 11β-HSD-1 and 11β-
HSD-2 expression in 
peripheral tissues. Male 
C57Bl/6J mice were fed a LFD 
(open bars) or HFD (chequered 
bars) for 12 weeks, and 11β-
HSD-1 (white bars) and 11β-
HSD-2 (grey bars) mRNA 
expression was determined in 
the liver (A) and gonadal (B), 
visceral (C) and subcutaneous 
(D) adipose tissues in the 
morning and evening. Mann-





This study aimed to characterize in detail, using standardized evaluations that control for 
housing and sampling conditions, the diet-induced changes that occur in basal activity of 
the HPA axis in the C567Bl/6J mouse model that develops obesity and insulin resistance, 
distinct features of the MetS. HFD feeding resulted in down regulation of the activity of 
the HPA axis, as reflected in decreased diurnal corticosterone concentrations, decreased 
11β-HSD-1-enzyme expression in peripheral tissues, and altered CRH and GR expression 
in the CNS (decreased in the morning and increased in the evening). These observations 
indicate that HFD induces complex changes in the diurnal regulation of the different 
components of the HPA axis. These changes are not unequivocally characterized by 
increased, but rather by decreased, HPA axis activity.  
As expected, HFD significantly increased both body weight and plasma insulin 
concentrations already within one week and HFD reduced diurnal corticosterone levels 
already within one week that persisted throughout the experiment. This persistent 
reduction in circulating corticosterone levels was not due to a shift in the diurnal peak of 
corticosterone and was evident from 1800-2000 h in the evening.   
Several mechanisms may explain the early decrease in diurnal corticosterone peak levels 
upon HFD. First, hypercortisolism in human obesity has not been established and cortisol 




















































































































































figure 4. Effect of high fat diet on 11β-HSD-1 and 11β-HSD-2 expression in peripheral tissues. 
Male C57Bl/6J mice were fed a LFD (open bars) or HFD (chequered bars) for 12 weeks, and 
11β-HSD-1 (white bars) and 11β-HSD-2 (grey bars) mRNA expression was determined in the 
liver (A) and gonadal (B), visceral (C) and subcutaneous (D) adipose tissues in the morning and 
evening. Mann-Whitney test, *P<0.05, **P<0.01, ***P<0.001.
discussion
This study aimed to characterize in detail, using standardized evaluations that control for housing 
and sampling conditions, the diet-induced changes that occur in basal activity of the HPA axis 
in the C567Bl/6J mouse model that develops obesity and insulin resistance, distinct features of 
the MetS. HFD feeding resulted in down regulation of the activity of the HPA axis, as reflected in 
decreased diurnal corticosterone concentrations, decreased 11β-HSD-1-enzyme expression in 
peripheral tissues, and altered CRH and GR expression in the CNS (decreased in the morning and 
increased in the evening). These observations indicate that HFD induces complex changes in the 
diurnal regulation of the different components of the HPA axis. T ese changes are not equivocally 


















As expected, HFD significantly increased both body weight and plasma insulin concentrations 
already within one week and HFD reduced diurnal corticosterone levels already within one week 
that persisted throughout the experiment. This persistent reduction in circulating corticosterone 
levels was not due to a shift in the diurnal peak of corticosterone and was evident from 1800-2000 h 
in the evening. 
Several mechanisms may explain the early decrease in diurnal corticosterone peak levels 
upon HFD. First, hypercortisolism in human obesity has not been established and cortisol secretion 
is increased in obese humans, primarily because of increased clearance and increased distribution 
volume of the circulating cortisol resulting in secondary central activation of the HPA axis (18, 19). 
Second, this decrease in diurnal corticosterone peak levels may reflect counteracting mechanisms 
directed towards prevention of further progression in insulin resistance, both centrally and in 
peripheral tissues. Third, circulating leptin concentrations increase proportionally to the fat mass 
gained (20) and leptin and insulin resistance have been documented to develop already within 
three days of high fat feeding (21). 
In accordance, HFD increased in CRH mRNA expression in the PVN and an increase in GR 
mRNA expression in the CA1 region of the hippocampus in the evening representing reduced 
negative feedback by decreased circulating corticosterone levels. This increase in GR mRNA in the 
CA1 region of the hippocampus also indicates that CNS areas important for specific types of learning 
and memory are relatively preserved in the presence of HFD and subsequent dampening of the 
HPA axis. In accordance, reduction of glucocorticoid levels in a specific mouse model of insulin 
resistance (db/db) reverses the cognitive impairment related to hippocampal neurons induced 
by insulin resistance (22). These findings imply that dampening of the HPA axis in the presence of 
insulin resistance, induced by HFD, might be a mechanism to rescue hippocampal neurons from 
impairments and to maintain normal cognitive function. In addition, both leptin and insulin can 
activate pro-opiomelanocortin (POMC) neurons (23), which produce ACTH. However, glucose 
sensing by POMC neurons is impaired in obese mice (24), which may result in insufficient adrenal 
stimulation by ACTH (diminished forward coupling between ACTH and corticosterone) resulting 
in decreased diurnal peak corticosterone and reduced negative feedback. In addition, the potency 
of ACTH is decreased in obesity (18).
Intriguingly, there is a disparity between the effects of HFD on the activity of the HPA axis 
in the morning as compared to the evening. Whereas the central activation in the evening can be 
easily explained by reduced negative feedback as a result of reduced peak corticosterone levels, 
the central inhibition of CRH and GR expression found in the morning in the presence of unaltered 
the circulating corticosterone levels, is very difficult to explain. To the best of our knowledge, such 
a disparity has not been previously documented or investigated. This further exemplifies that HFD 
induces complex changes in the diurnal regulation of the different components of the HPA axis. It 
is also likely that other factors outside the individual components of the HPA axis influence these 
complex effects of dietary intervention. Reduction of hypothalamic CRH expression in the morning 
might include the following mechanisms. For instance, induction of leptin resistance in the presence 
of obesity induces an increase in endocannabinoid tone (25, 26), which could lead to suppression 
of CRH. However, leptin resistance induced by high fat feeding is selective and does not impact on 
autonomic nervous system activity (27). Thus it could be speculated that hyperleptinemia dampens 
CRH expression and release in the face of selective sensitivity of the central HPA axis. It has also 
been shown in in vitro studies that leptin can reduce the sensitivity of adrenal cortex cells to ACTH, 
47
3
thereby reducing circulating corticosterone levels (28, 29). However, the present data do not permit 
firm conclusions in this respect. In addition, a true effect of the diet per se can not be excluded as 
no differences were observed in plasma corticosterone levels in the morning, although it is well 
possible that small changes in circulating corticosterone levels at the moment of the diurnal nadir 
are not detected. The observed decreased expression of hypothalamic GR expression, however, 
is not explained because it suggests increased corticosterone exposure.Down regulation of CRH 
mRNA in the morning, was accompanied by downregulation of CRH mRNA and in the amygdala. 
Activation of the amygdala promotes HPA-activation and previous studies in rats have shown that 
increase in circulating glucocorticoids increase (30) whereas adrenalectomy decreases (31) CRH in 
the amygdala. Furthermore, increased CRH in the amygdala mediates anxiety-like behavior during 
stress (32) and high fat diet decreases anxiety-like behaviors facilitating stress recovery (33, 34). 
Thus, HFD-induced reduction of CRH expression in the amygdala enables protection from further 
exposure to systemic glucocorticoids. 
In accordance, the effects of HFD on the peripheral activity of the HPA axis were characterized 
by reduced mRNA expression of 11β-HSD-1 in adipose tissues. It has been proposed that this may 
reflect a mechanism to counteract tissue-specific insulin resistance (35). These differential, fat 
depot-specific effects are in agreement with a recently- proposed, dynamic and depot-selective 
relationships between adipose tissue 11β-HSD-1-activity and fat mass (35). HFD increases lipoprotein 
lipase activity (36), which would direct circulating triglycerides towards peripheral adipose tissues 
for storage. Corticosterone impairs glucose tolerance (37) and is a lipolytic hormone (38). Therefore 
down regulation of 11β-HSD-1 expression would protect the adipose tissue from further insulin 
resistance. These observations are further strengthened by the fact that 11β-HSD-2 expression in 
the same tissues was not affected, resulting into overall reduction of glucocorticoid exposure of 
the tissues.
In conclusion, we found that HFD has profound effects on the basal, thus non-stressed, activity 
of the HPA axis, reflected in reduced diurnal corticosterone concentrations, distinct expression of 
CRH in the CNS across the diurnal rhythm, and reduced 11β-HSD-1-enzyme expression in peripheral 
fat tissues. The observed effects in this study, both in the CNS and peripheral adipose tissues 
(downregulation of CRH mRNA and 11β-HSD-1 enzyme mRNA, respectively), are in agreement 
with the well-known metabolic effects of glucocorticoids, that are directed towards recruitment 
and augmentation of energy stores. In the presence of HFD induced obesity or palatable foods, 
the HPA axis adapts.
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introduction: A period of glucocorticoid (GC) overexposure, as observed in Cushing’s syndrome 
(CS), is associated with the metabolic syndrome (MetS) and cardiovascular diseases. These changes 
persist even after long-term correction of GC excess, and may in fact be permanent. We performed 
a mouse study to identify factors that modulate metabolic recovery from a period of overexposure 
to GC.
Methods: Male C57Bl/6J mice, fed a low fat (LFD) or high fat diet (HFD), received corticosterone 
(CORT) (50µg/ml) or vehicle in the drinking water for 4 wks, followed by a washout period of 8 wks. 
Plasma circadian CORT, lipids, insulin, and glucose levels were assessed at regular intervals. Insulin 
sensitivity was assessed by hyperinsulinemic-euglycemic clamp and lean body- and fat masses 
were analyzed at week 12.
results: CORT treatment increased plasma CORT levels, food intake and plasma insulin and lipids in 
both diets. Abrogation of CORT treatment normalized CORT levels, food intake and body weight. 
At week 12, plasma insulin levels were still significantly higher in CORT-treated mice on both diets, 
and HFD-fed CORT-treated mice had persistently decreased lean body mass and higher fat mass. 
conclusion: In mice, a period of CORT excess induces long-lasting metabolic changes. The changes 
in body composition were present only in the presence of HFD. These observations indicate that 
diet-dependent effects of CORT might contribute to the persistent adverse cardiovascular risk 































In humans, prolonged excessive exposure to glucocorticoids (GC) as seen in Cushing’s syndrome 
(CS), is associated with an increased incidence of the metabolic syndrome (MetS), a clustering of 
cardiovascular risk factors such as increased blood pressure, dyslipidemia and insulin resistance, 
and increased cardiovascular morbidity and mortality (1). Increased GC exposure changes eating 
behavior and food preferences facilitating the development of obesity and the MetS (2, 3). 
Intriguingly, patients with CS remain at increased cardiovascular risk, even despite long-term 
successful correction of GC excess (4). However, the causal relation between the episode of cortisol 
overexposure and long-term changes in the cardiovascular risk factors is not established and the 
modifiers of normalization are unknown and are difficult to assess in humans because of the rarity 
and heterogeneity of CS. 
Representative animal models that enable to study the metabolic effects of corticosterone 
(CORT) overexposure are limited, whereas in humans GCs induce weight gain and increase 
appetite (5), in rats high CORT concentrations (using either chronic stressors or via implantation 
of subcutaneous (sc) CORT pellets or intraperitoneal (ip) injections) decrease intake of standard 
chow (6). These catabolic effects of GC in rodents can be counteracted by adding 30% sucrose 
to regular chow of CORT-treated rats. Indeed, when CORT-treated rats with sc pellets were given 
regular chow with the addition of sucrose, these rats became markedly hyperinsulinemic and 
hypercholesterolemic, and developed visceral obesity (7). Thus, the addition of sucrose to chow 
appears to be a prerequisite for the development of obesity in rodents exposed to high CORT (6).
Chronic oral CORT supplementation was recently reported to induce impressive metabolic 
changes including weight gain, increased adiposity, elevated plasma, insulin and triglyceride levels, 
and hyperphagia (8). Since these features resemble the changes observed in individuals suffering 
from MetS, this represents a model for hypercortisolemia and stress-related obesity. 
In the present study, we hypothesized that a period of overexposure to GC in mice would 
result in long-term or even permanent metabolic changes, and that this would be affected by the 
composition of the diet.
Materials and MetHods
experimental procedures
Mice, housing, cort supplementation, and diets
Eight-week old male C57Bl/6J mice (Charles River, Maastricht, The Netherlands) were single housed 
in a separate room from other experimental animals in the facility to minimize environmental 
stressors, and maintained on a 12 h:12 h light-dark cycle (lights on 7 a.m.), with ad libitum access 
to food and drinking water. 
Experiment 1: C57Bl/6J mice were fed a low fat diet (10 energy % lard fat, D12451B, Research 
Diet Services, Inc., New Brunswick, US.) (LFD) and after 4 weeks (at 12 weeks of age), they were 
matched for weight, the levels of plasma triglycerides, non-esterified free fatty acids and cholesterol, 
and randomized to receive either 50µg/ml CORT (Sigma-Aldrich, Manchester, UK) in the drinking 
water (containing 0.25% ethanol as vehicle), or 0.25% ethanol as vehicle only in the drinking water 
(control group), for 4 weeks. At week 12 (control group n=10, CORT-group n=10) dual energy X-ray 
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absortiometry (DEXA) analysis to determine body composition and hyperinsulinemic-euglycemic 
clamp analysis was performed to determine the insulin sensitivity. 
Experiment 2: C57Bl/6J mice were fed a high fat diet (45 energy % lard fat, D12451, Research 
Diet Services, Inc., New Brunswick, US) (HFD) from 10 weeks of age and after reaching 12 week of 
age, were matched for weight, plasma triglycerides, non-esterified free fatty acids and cholesterol 
and randomized to receive either 50µg/ml CORT (Sigma-Aldrich) in the drinking water (containing 
0.25% ethanol as vehicle), or to drinking water with 0.25% ethanol as vehicle only (control group), 
for four weeks. At week 12 DEXA analyses (n=10) was performed to determine body composition. 
Hyperinsulinemic-euglycemic clamp analysis was performed to determine the insulin sensitivity 
in a subset of mice (control group n=6, CORT-group n=7).
sampling of circadian corticosterone, hormone, and lipid measurements
Blood for analysis of plasma CORT levels was sampled in both experiments at baseline, and at week 
4, 8 and 12 during the first light hour at 07.00 h, at 12.00 h, during the last light hour at 18.00 h, 
and at 22.00 h (three hours after the onset of the dark phase). During the dark phase samples 
were collected in red light conditions. All CORT samples were obtained within 90 seconds from 
disturbing the cage, via tail incision, allowing the mouse to move freely on top of the home cage 
(9). Plasma insulin, glucose, total cholesterol, triglycerides and non-esterified free fatty acids were 
sampled after overnight fast at baseline, week 4, 8 and 12. Body weight, food intake and water 
intake were measured weekly.
dual-energy x-ray absorptiometry (dexa) scan 
Body composition was measured at week 12 by DEXA using the Norland pDEXA Sabre X-Ray 
Bone Densitometer (Norland, Hampshire, UK). Before measuring, mice were anaesthetized with 
a combination of 6.25 mg/kg acepromazine (Alfasan, Woerden, the Netherlands), 6.25 mg/kg 
midazolam (Roche, Mijdrecht, the Netherlands), and 0.31 mg/kg fentanyl (Janssen-Cilag, Tilburg, 
the Netherlands). Mice were scanned in toto, and the heads were subsequently excluded from 
the analysis due to the inability of the DEXA scan to accurately determine the composition of the 
tissue underneath the skull.
Hyperinsulinemic-euglycemic clamp study
Hyperinsulinemic-euglycemic clamp studies were performed at week 12 in postabsorptive 
(i.e., overnight fasted) condition. Mice were anesthetized with 6.25 mg/kg acepromazine (Alfasan, 
Woerden, the Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, the Netherlands), and 
0.31 mg/kg fentanyl (Janssen-Cilag, Tilburg, the Netherlands). First, the basal rate of glucose turnover 
was determined by giving a primed (0.5 µCi) continuous (0.9 µCi/h) intravenous (iv) infusion of 
D-[3-3H]-glucose (37 MBq) (GE Healthcare, Little Chalfont, UK) for 60 min. Subsequently, insulin (Novo 
Nordisk, Bagsværd, Denmark) was administered in a primed (3.7 mU) continuous 6.1 mU/h for LFD 
fed mice and 11.25mU/h for HFD-fed mice as iv infusion for 90 min to attain steady-state circulating 
insulin levels. Every 10 min, the plasma glucose concentration was determined via tail vein bleeding 
(<3 µl) (Accu-chek, Sensor Comfort; Roche Diagnostics GmbH, Mannheim, Germany) and the iv 
infusion rate of a 12.5% D-glucose solution was adjusted to maintain euglycaemia. Blood samples 
(60 µl) were taken during the basal period (after 50 and 60 min) and during the hyperinsulinaemic 
period (after 70, 80 and 90 min) to determine plasma concentrations of glucose, insulin and specific 






























All animal experiments were performed in accordance with the regulations of Dutch law 
on animal welfare and the institutional ethics committee for animal procedures from the Leiden 
University Medical Center approved the protocol.
Hormone and lipid measurements
Plasma CORT levels were determined by radioimmunoassay (MP Biomedicals LCC, Orangeburg, 
NY). Plasma levels of total cholesterol, triglycerides and non-esterified free fatty acids were 
measured with enzymatic colorimetric reaction (Roche diagnostics GmbH, Mannheim; and Wako 
Pure Chemical Industries, respectively), plasma insulin was measured with an ELISA (Crystal Chem 
Inc., Downers Grove, IL, USA) and plasma glucose with a hexokinase method (Instruchemie, 
Delfzijl, The Netherlands). Homeostasis model index of insulin (HOMA-IR) was calculated by 
multiplying fasting insulin concentration (µU/ml) with fasting glucose (mmol/l), and dividing 
with 22.5 (10 Mather 2009).
calculations and statistical analysis
Data from the hyperinsulinemic-euglycemic clamp studies were calculated as previously described 
by Voshol et al. 2001 (11). The rate of glucose uptake (µmol/min/kg) was calculated in the basal period 
as well as during the steady-state hyperinsulenemia (70, 80 and 90 minutes of the clamp) as the 
rate of tracer infusion (dpm/min) divided by the plasma-specific activity of 3H-glucose (dpm/µmol) 
in the plasma. Endogenous glucose production (µmol/min/kg) was calculated as the difference 
between the tracer-derived rate of glucose uptake and the glucose infusion rate. Glucose uptake 
as well as glucose production were corrected for body weight.
Data are presented as means ± SD. Statistical differences were calculated using Mann-Whitney 
test for non-parametric data, with GraphPad Prism, version 5.01. P<0.05 was considered as statistically 
significant.
results
pilot experiment for the determination of optimal cort dose:
Prior to both experiments, we performed a dose finding study in mice fed HFD with 12.5 µg/ml (n=2), 
25 µg/ml (n=4) and 50 µg/ml (n=2) of CORT and control receiving 0.25% ethanol (n=2) as vehicle 
for four weeks to determine the optimal CORT dose. These dosages were chosen based upon a 
previous study (8) that documented profound metabolic effects with CORT 100 µg/ml and less 
pronounced effects with 25 µg/ml. Based upon our dose finding study, we chose 50µg/ml CORT in 
the drinking water for our subsequent experiments as this dose led to the most profound increases 
in food intake and body weight as well as in plasma cholesterol (data not shown).
cort treatment increases plasma cort concentrations and affects 
circadian rhythm of cort 
A circadian rhythm of CORT was present at baseline in both dietary conditions (Fig. 1A and B) 
and chronic high doses of CORT (50µg/ml) increased plasma CORT levels and affected circadian 
rhythm, Fig. 1C and D, respectively). At week 8 (four weeks after abrogation of CORT), in the LFD 
experiment CORT-treated animals had recovered and were not different from the controls, while 
in the HFD experiment, the peak (18.00 h) circadian (endogenous) CORT concentrations were 
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-22% lower in CORT-treated animals compared to controls (Fig. 1E and F, respectively). At week 12 
circadian CORT levels were equal to the controls.
cort treatment induces transient changes in food intake and bodyweight
Experiment 1 (LFD): CORT treatment increased food intake (by 14% vs controls at week 1 to 27% 
at week 4) (Fig. 2C). After removal of CORT, food intake rapidly decreased by -29% vs controls 
returning to the level of the control group at week 6. This increase in food intake was not 
translated into an increase in bodyweight, being comparable between the groups during the 
CORT treatment. Removal of CORT transiently decreased bodyweight in the CORT group at 
week 5 and 6 (by -5%, and -4%, respectively), but body weight was not different from controls 
thereafter (Fig. 2A). CORT treatment increased water intake (with CORT in it) up to 3-fold 
during the treatment period and decreased close to the level of the controls after removal of 
CORT from the drinking water, however, still remaining significantly higher to the end of the 
experiment (Fig. 2E).
Experiment 2 (HFD): CORT treatment increased food intake by +19% vs controls after the 
first week (Fig. 2D), with a concomitant increase in bodyweight that was significant at week 3 and 
remained significantly higher at week 4 and 5 (+11%, +19%, and +9%, respectively) (Fig. 2B) when 
compared to the controls. After removal of CORT, food intake normalized at week 6, and did not 
differ from controls for the remainder of the experiment. CORT treatment did not affect water 
intake except after removal of CORT from the drinking water at week 5 and 10 (by -21% and -10%, 
respectively) when water intake was significantly lower in the CORT-treated group when compared 
to controls (Fig 2F).
12.5 µg/ml (n=2), 25 µg/ml (n=4) and 50 µg/ml (n=2) of CORT and control receiving 
0.25% ethanol (n=2) as vehicle for four weeks to determine the optimal CORT dose. 
These dosages were chosen based upon a previous study (8) that documented 
profound metabolic effects with CORT 100 µg/ml and less pronounced effects with 
25 µg/ml. Based upon our dose finding study, we chose 50µg/ml CORT in the 
drinking water for our subsequent experiments as this dose led to the most profound 
increases in food intake and body weight as well as in plasma cholesterol (data not 
shown). 
 
CORT treatment increases plasma CORT concentrations and affects circadian 
rhythm of CORT  
A circadian rhythm of CORT was present at baseline in both dietary conditions (Fig. 
1A and B) and chronic high doses of CORT (50µg/ml) increased plasma CORT levels 
and affected circadian rhythm, Fig. 1C and D, respectively). At week 8 (four weeks 
after abrogation of CORT), in the LFD experiment CORT-treated animals had 
recovered and were not different from the controls, while in the HFD experiment, the 
peak (18.00 h) circadian (endogenous) CORT concentrations were -22% lower in 
CORT-treated animals compared to controls (Fig. 1E and F, respectively). At week 12 
circadian CORT levels were equal to the controls. 
Figure 1. Effect of CORT treatment on circadian plasma CORT of mice fed a low fat diet (A, B, C and 
D) (control group: open bars, CORT group: light grey bars) or high fat diet (E, F, G and H) (control 
group: dark grey bars, CORT group: black bars) at baseline, week 4, week 8 and week 12, Mann-
Whitney test, *P<0.05, ***P<0.001. 
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Ncort treatment induces transient changes in plasma lipids
CORT treatment increased plasma levels of triglycerides and non-esterified free fatty acids 
significantly in the LFD experiment at week 4 (by +56% and +24%, respectively) (Table 1). In the 
HFD experiment, additionally, significant increases vs controls were observed in the plasma levels 
of total cholesterol and non-esterified free fatty acids at week 4 (+38% and +21%, respectively) 
(Table 1). At week 8, plasma triglycerides levels were significantly higher in the HFD group (by 
+21% vs controls) (Table 1). 
insulin and HoMa-ir are increased long-term by cort treatment 
As expected, when compared to controls, CORT treatment significantly increased plasma 
insulin concentrations on both diets (LFD: 8-fold and HFD: 3-fold increase at week 4) (Table 1), 
and remained significantly higher after removal of CORT treatment. Of note; insulin levels did 
not markedly decrease in CORT-treated animals between week 8 (LFD: +83% and HFD: +67%) 
figure 2. Effect of CORT treatment on body weight, food intake and water intake of mice fed 
a low fat diet (control group: white circles, CORT group: light grey squares) (A, C and E) or 
high fat diet (control group: dark grey circles, CORT group: black squares) (B, D and F), Mann-
Whitney test, *P<0.05, $P<0.01, #P<0.001.
CORT treatment induces transient changes in food intake and bodyweight 
Experiment 1 (LFD): CORT treatment increased food intake (by 14% vs controls at week 1 to 
27% at week 4) (Fig. 2C). After removal of CORT, food intake rapidly decreased by -29% vs 
controls returning to the level of the control group at week 6. This increase in food intake was 
not translated into an increase in bodyweight, being comparable between the groups during 
the CORT treatment. Removal of CORT transiently decreased bodyweight in the CORT 
group at week 5 and 6 (by -5%, and -4%, respectively), but body weight was not different 
from controls thereafter (Fig. 2A). CORT treatment increased water intake (with CORT in it) 
up to 3-fold during the treatment period and decreased close to the level of the controls after 
removal of CORT from the drinking water, however, still remaining significantly higher to 
the end of the experiment (Fig. 2E). 
Experiment 2 (HFD): CORT treatment increased food intake by +19% vs controls after the 
first week (Fig. 2D), with a concomitant increase in bodyweight that was significant at week 
3 and remained significantly higher at week 4 and 5 (+11%, +19%, and +9%, respectively) 
(Fig. 2B) when compared to the controls. After removal of CORT, food intake normalized at 
week 6, and did not differ from controls for the remainder of the experiment. CORT treatment 
did not affect water intake except after removal of CORT from the drinking water at week 5 
and 10 (by -21% and -10%, respectively) when water intake was significantly lower in the 
CORT-treated group when compared to controls (Fig 2F). 
 
Figure 2. Effect of CORT 
treatment on body weight, 
food intake and water intake of 
mice fed a low fat diet (control 
group: white circles, CORT 
group: light grey squares) (A, 
C and E) or high fat diet 
(control group: dark grey 
circles, CORT group: black 
squares) (B, D and F), Mann-













and week 12 (LFD: +67% and HFD: +69%) (Table1). Plasma glucose was significantly decreased 
by in LFD experiment at week 8 and 12 (-14% and -17%, respectively) and by -21% in the HFD 
experiment at week 4 -in the CORT group (Table 1). Changes in plasma insulin and glucose 
induced by CORT treatment, were reflected as decreased insulin sensitivity as reflected in 
HOMA-IR. In both experiments CORT significantly increased HOMA-IR at week 4 (LFD: 8-fold 
and HFD: 3-fold) (Table 1). Furthermore, HOMA-IR at week 8 was still significantly increased 
by +69% in the HFD experiment after CORT treatment (Table 1), and +45% increased in the LFD 
experiment at week 12, which however, did not reach significance, (Table 1) when compared 
to the controls (Table1).
cort treatment induces long-lasting changes in body composition only in 
the presence of Hfd 
In the HFD experiment, after 12 weeks, CORT treatment significantly reduced lean body mass 
(23±3% vs. 28±4% of total body weight, CORT vs controls, respectively (Fig. 3C), and significantly 
increased fat mass (55±5% vs. 64±7% of the total body weight) (Fig. 3D). However, long-lasting 
changes in body composition were not observed in the LFD experiment (Fig 3A and B).
cort treatment does not affect endogenous glucose production or glucose 
disposal in the long-term 
Endogenous glucose production and glucose disposal, as derived from the hyperinsulinemic-
euglycemic clamp studies, were not different between the CORT-treated and the control group in 
the LFD experiment (Fig. 4A and B), nor in the HFD experiment (Fig. 4C and D) at week 12.





Total cholesterol (mmol) Triglycerides (mmol) Non-esterified free fatty acids (mmol)
LFD HFD LFD HFD LFD HFD
Control CORT Control CORT Control CORT Control CORT Control CORT Control CORT
0 3.4±0.3 3.4±0.3 3.2±0.7 3.3±0.4 0.7±0.2 0.7±0.3 1.1±0.4 1.1±0.3 1.4±0.3 1.4±0.3 1.6±0.3 1.8±0.3
4 3.0±0.3 3.2±0.6 3.5±0.7 4.8±0.6b 0.9±0.2 1.4±0.3c 1.1±0.3 1.3±0.2 1.7±0.3 2.1±0.4a 1.8±0.2 2.2±0.3b
8 3.1±0.3 2.9±0.4 3.9±0.8 4.0±0.4 0.7±0.1 0.8±0.3 1.5±0.6 1.8±0.4a 1.6±0.2 1.5±0.2 1.7±0.3 1.9±0.3




Insulin (ng/ml) Glucose (mmol) HOMA-IR
LFD HFD LFD HFD LFD HFD
Control CORT Control CORT Control CORT Control CORT Control CORT Control CORT
0 0.6±0.3 0.6±0.3 0.6±0.3 0.5±0.2 3.6±0.7 3.8±1.0 5.3±1.1 5.2±0.7 2.3±0.8 2.2±0.9 3.1±1.5 2.7±1.0
4 0.6±0.2 4.8±2.2c 1.1±0.3 4.0±1.1c 4.1±0.9 3.4±0.7 4.3±0.7 3.4±0.7a 2.3±0.6 17.7±10.6b 5.0±1.8 14.4±3.7c
8 0.6±0.2 1.1±0.8a 0.6±0.3 1.0±0.4a 4.2±0.6 3.6±0.6a 5.2±1.1 5.2±1.2 2.5±0.7 4.3±2.7 3.4±1.6 5.7±2.5a
12 0.6±0.4 1.0±0.4a 1.3±0.4 2.2±1.0a 4.8±0.6 4.0±0.6b 3.9±1.1 3.1±0.7 2.9±1.9 4.2±1.7 5.3±2.4 7.4±4.0































CORT treatment induces long-lasting changes in body composition only in the 
presence of HFD  
In the HFD experiment, after 12 weeks, CORT treatment significantly reduced lean 
body mass (23±3% vs. 28±4% of total body weight, CORT vs controls, respectively 
(Fig. 3C), and significantly increased fat mass (55±5% vs. 64±7% of the total body 
weight) (Fig. 3D). However, long-lasting changes in body composition were not 
observed in the LFD experiment (Fig 3A and B). 
Figure 3. Effect of CORT treatment on 
body composition of mice fed a low fat 
diet (A and B) (control group: open 
bars, CORT group: light grey bars) or 
high fat diet (C and D) (control group: 
dark grey bars, CORT group: black 







CORT treatment does not affect endogenous glucose production or glucose 
disposal in the long-term  
Endogenous glucose production and glucose disposal, as derived from the 
hyperinsulinemic-euglycemic clamp studies, were not different between the CORT-
treated and the control group in the LFD experiment (Fig. 4A and B), nor in the HFD 
experiment (Fig. 4C and D) at week 12. 
Figure 4. Effect of CORT treatment on 
endogenous glucose production and 
glucose disposal during basal period of 
glucose infusion (basal) and 
hyperinsulinemia (hyper) in mice fed a 
low fat diet (A and B) (control group: 
open bars, CORT group: light grey 
bars) or high fat diet (C and D) (control 
group: dark grey bars, CORT group: 



















































































































































































































































































































































figure 3. Effect of CORT treatment on body composition of mice fed a low fat diet (A and B) 
(control group: open bars, CORT group: light grey bars) or high fat diet (C and D) (control 
group: dark grey bars, CORT group: black bars), Mann-Whitney test, **P<0.01, ***P<0.001.
figure 4. Effect of CORT treatment on endogenous glucose production and glucose disposal 
during basal period of glucose infusion (basal) and hyperinsulinemia (hyper) in mice fed a 
low fat diet (A and B) (control group: open bars, CORT group: light grey bars) or high fat diet 
(C and D) (control group: dark grey bars, CORT group: black bars) at week 12.
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body mass (23±3% vs. 28±4% of total body weight, CORT vs controls, respectively 
(Fig. 3C), and significantly increased fat mass (55±5% vs. 64±7% of the total body 
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We demonstrated that a period of overexposure to GCs induces long lasting, potentially permanent, 
changes in metabolic parameters, but only in the presence of HFD. In HFD-animals increased insulin 
levels and altered body composition did not normalize even after an 8-week wash out period, when 
parameters like food intake and body weight had returned to control levels for about 6 weeks. 
As anticipated, in our study high CORT levels increased food intake and induced metabolic 
changes that resemble the MetS, like an increase in plasma insulin levels, lipids, and body fat, 
irrespective of a high- or low fat diet. These effects were reversible after normalization of CORT 
levels when exposed to LFD, but some irreversible changes were observed with HFD exposure. 
HFD adversely affected body composition even after long-term withdrawal of high CORT exposure. 
This indicates that HFD aggravates the adverse long-term metabolic effects of transient high CORT 
exposure. This points at a crucial role for dietary composition in the development of the metabolic 
syndrome in conditions with periodic excessive CORT exposure.
Supra-physiological CORT levels were readily induced using oral CORT in the drinking water. 
This treatment with CORT also affected circadian CORT rhythm impairing the degree of variations 
in plasma concentrations. After discontinuation of CORT treatment, circadian rhythm gradually 
returned to the level of the controls at week 12, although evening (18.00 h) CORT peak was still 
decreased at week 8 in the HFD experiment. This indicates that incomplete recovery of the HPA axis 
after a period of exogenous supra-physiological CORT supplementation, as has been documented 
extensively in humans both after treatment for CS (12) and in patients previously exposed to 
exogenous supra-physiological GCs (13) might be dependent on the composition of the diet.
CORT treatment increased food intake on both diets but bodyweight increased only on 
HFD. It has been previously shown that high CORT levels stimulate voluntary food intake dose-
dependently (6, 14, 15). In addition, in case of different food availability, food preference changes 
towards more energy-rich “palatable“ food (16) serving the evolutionary purpose to attain the 
most efficient fuels to counteract the adverse changes in insulin sensitivity that occur during 
stress (17). With increasing insulin and GC levels food intake is even stimulated in the presence of 
less palatable foods (6, 18, 19). In agreement, in the present experiments with LFD and HFD, the 
increased plasma CORT levels were accompanied by increases in circulating insulin, triglycerides, 
cholesterol, and free fatty acid levels. The increased food intake only increased body weight 
on HFD, suggesting that the increase in food intake on LFD was just sufficient to compensate 
for the catabolic effects of increased CORT levels. However, higher dosages of CORT than the 
one used in our study were able to increase bodyweight on regular chow diet (8). Intriguingly, 
it seems that the increase in fat mass remains present even after a washout from the increased 
plasma CORT levels.
Water intake, and therefore CORT intake was increased only in the LFD- but not in the HFD 
experiment in the CORT-treated group. However, even when consuming a higher amount of CORT 
during LFD the reversibility of the metabolic changes after LFD (but not after HFD) was complete, 
which strengthens our conclusions on the modulatory role of the diets per se.
Although body weight returned to that of the controls after discontinuation of CORT 
treatment, on HFD, the increase in plasma triglycerides was still present at week 8, and insulin 
concentrations remained elevated even at week 12. However, endogenous glucose production 
and disposal assessed with hyperinsulenemic-euglycemic clamps at the end of the study did not 






























Whereas the effects on body weight were transient, long-lasting changes in body composition 
were found on HFD, where reduced lean body mass and increased fat mass was observed even 
after 12 experimental weeks. These effects of CORT treatment on body composition were not 
observed in the LFD experiment. Chronically administered GCs facilitate muscle atrophy (20) and 
increase visceral fat mass in mice (8, 21). In the human, the equivalent of chronic high GC is CS, a 
rare clinical syndrome where patients are exposed to increased adrenal cortisol secretion due to 
an ACTH producing pituitary or ectopic tumor or due to an adrenal adenoma (1). Patients with CS 
have increased prevalence of the MetS (22, 23), but intriguingly, after one year of remission still 
have increased waist circumference (24, 25) and even after long-term remission higher visceral fat 
mass was observed without affecting body mass index (26).
The fact that the long-lasting changes observed in mice after a period of exposure to 
high CORT persist for a longer period of time in the presence of HFD is intriguing in view of 
the incomplete reversibility of metabolic changes observed in patients with CS after correction 
for hypercortisolism. Humans exposed to stress levels of GC, like in CS, will direct their food 
preference towards highly palatable foods, in agreement with the biological effects of GC, thereby 
aggravating the adverse cardiometabolic effects and thus facilitating the development and 
persistence of MetS. Epidemiological data also indicate an increased prevalence of the metabolic 
syndrome in conditions associated with alterations in the HPA axis, like in anxiety and depression, 
after medical treatment with GC, and also in sleep disorders (27, 28). Because it appears that 
these diet-dependent effects of CORT during stress strongly facilitate the persistent adverse 
cardiovascular risk profile, the interactions between the availability of ‘fast food’ and every-
day-stress are novel features to be accentuated in future studies on cardiovascular morbidity 
and mortality.
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introduction: The role of glucocorticoids in atherosclerosis development is not clearly established. 
Human studies show a clear association between glucocorticoid excess and cardiovascular disease, 
whereas most animal models indicate an inhibitory effect of glucocorticoids on atherosclerosis 
development. These animal models, however, neither reflect long-term glucocorticoid overexposure 
nor display human-like lipoprotein metabolism.
aim: To investigate the effects of transient and continuous glucocorticoid excess on atherosclerosis 
development in a mouse model with human-like lipoprotein metabolism upon feeding a Western-
type diet.
Methods: Pair-housed female APOE*3-Leiden.CETP (E3L.CETP) mice fed a Western-type containing 
0.1% cholesterol for 20 weeks were given corticosterone (50 µg/ml) for either 5 (transient group) 
or 17 weeks (continuous group), or vehicle (control group) in the drinking water. At the end of the 
study, atherosclerosis severity, lesion area in the aortic root, the number of monocytes adhering 
to the endothelial wall and macrophage content of the plaque were measured. 
results: Corticosterone treatment increased body weight and food intake for the duration of the 
treatment and increased gonadal and subcutaneous white adipose tissue weight in transient group 
by +35% and +31%, and in the continuous group by +140% and 110%. Strikingly, both transient and 
continuous corticosterone treatment decreased total atherosclerotic lesion area by -39% without 
lowering plasma cholesterol levels. In addition, there was a decrease of -56% in macrophage content 
of the plaque with continuous corticosterone treatment, and a similar trend was present with the 
transient treatment.
conclusion: Increased cortiosterone exposure in mice with human-like lipoprotein metabolism 
has beneficial, long-lasting effects on atherosclerosis, but negatively affects body fat distribution 
by promoting fat accumulation in the long-term. This indicates that the increased atherosclerosis 
observed in humans in states of glucocorticoid excess may not be related to cortisol per se, but 



















Atherosclerosis develops as a result of a chronic inflammatory response in an injured vessel wall (1), 
which is preceded by accumulation of leukocytes and fat deposition, leading to plaque formation 
(2). The initial mechanisms in atherogenesis, however, are still incompletely understood. 
The role of glucocorticoids (GC) in the development of atherosclerosis is not yet clearly 
established in humans or in animals and is, at least, dependent on individual’s (3, 4) or animal’s 
(5) exposure to appropriate levels of adrenal steroids. Human data show an association between 
increased GC secretion and cardiovascular disease even after long-term successful correction 
of GC excess (6), whereas previous studies in animals, e.g. rabbits (7, 8, 9, 10, 11) and dogs (12) 
using either natural or synthetic GC, suggest an atheroprotective role of GC. On the other hand, 
11β-dehydrogenase type 2 (11βHSD2) deficient mice, in which the activation of the mineralocorticoid 
receptor (MR) by GCs cannot be prevented, have an increased atherosclerotic plaque development 
(13), suggesting that increased activation of the MR promotes atherosclerotic plaque formation. 
However, a recent study demonstrated that adrenalectomy, which removes endogenous GC, 
stimulated the formation of initial atherosclerotic lesions in low-density-lipoprotein receptor 
knockout mice (5).
Only a limited number of studies have evaluated the effect of endogenous GC excess on 
atherosclerosis development in mice. These studies, that used chronic stress to increase endogenous 
GC, reported either an increase (14, 15) or no effect (16) on atherosclerosis development in ApoE-
deficient mice. However, chronic stress, in addition to increasing GC, induces other complex 
endocrine and metabolic changes, for instance increased sympathetic outflow (17) that may affect 
atherosclerosis development. These mouse models therefore do not reflect long-term endogenous 
GC overexposure, like in Cushing’s syndrome (CS) in humans. Furthermore, ApoE-deficient mice 
do not reflect human-like lipoprotein metabolism and have a deviant immune status compared 
to wild-type mice (18).
In the present study, our aim was to investigate the effects of GC excess on atherosclerosis 
development in the APOE*3-Leiden.CETP (E3L.CETP) mouse, a well-established model for human-
like lipoprotein metabolism that is prone to develop atherosclerosis upon feeding a cholesterol-
containing Western-type diet (19) and is responsive to all hypolipidemic drugs used in the clinic 
similar to humans (20-23) The latter is in sheer contrast to other mouse models for hyperlipidemia 
and atherosclerosis including apoE-knockout and LDL receptor-knockout mice. We administered 
corticosterone (CORT) non-invasively via the drinking water, and based on the clinical observation 




This study was carried out in strict accordance with the regulations of Dutch law on animal welfare, 
and the institutional ethics committee for animal procedures of Leiden University. The protocol was 
approved by the institutional ethics committee for animal procedures of Leiden University (Permit 
Number: 10132 and for the pilot experiment: 08221) and all efforts were made to minimize suffering.
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Mice, housing, corticosterone supplementation, and diets
Human CETP expressing transgenic mice, which express CETP under control of its natural flanking 
regions, were crossbred in our own animal facility with E3L mice to obtain the heterozygous E3L.
CETP mice on a C57Bl/6 background (24). Female mice (10-16 weeks of age) were pair housed and 
maintained on a 12 h:12 h light-dark cycle (lights on 7 a.m.) in a climate controlled environment, 
with ad libitum access to food and drinking water. Mice were fed a Western-type diet containing 
0.1% cholesterol (Diet T + 0.1% cholesterol, Arie Blok Diervoeding, Woerden, the Netherlands) for 
a period of three weeks after which they were matched for age, plasma cholesterol, triglycerides, 
phospholipids, age and bodyweight and then randomized to receive CORT (Sigma-Aldrich, 
Manchester, UK) at a concentration of 50 µg/ml in the drinking water with 0.25% ethanol as vehicle 
for five weeks (transient group, n=17), continuously for the entire duration of the experiment 
(seventeen weeks) (continuous group, n=21), or vehicle (control group, n=19). Food and bodyweight 
were recorded weekly. At the end of the experiment mice were decapitated within 90 seconds 
from disturbing the cage and trunk blood was collected. Gonadal and subcutaneous fat pads were 
removed from each mouse by the same person to reduce inter-observer variation. The same area 
of subcutaneous fat was removed from each mouse excluding the inguinal lymph node. Fat pads 
and adrenals were weighed using a micro scale, and frozen in liquid nitrogen.
pilot experiment for the determination of optimal cort dose
Prior to experiment, we performed a dose finding study in male C57Bl/6J mice fed HFD with 
12.5 µg/ml (n=2), 25 µg/ml (n=4) and 50 µg/ml (n=2) of CORT, and control receiving 0.25% ethanol 
(n=2) as vehicle for four weeks to determine the optimal CORT dose. These dosages were chosen 
based upon a previous study (25) that documented profound metabolic effects with CORT 100 µg/ml 
and less pronounced effects with 25 µg/ml. Based upon our dose finding study, we chose 50 µg/ml 
CORT in the drinking water for our subsequent experiments as this dose led to the largest increases 
in food intake and body weight as well as in plasma cholesterol. Because male mice do not readily 
develop atherosclerosis and the known models are in majority female models, we used female 
mice for the purpose to study the atherosclerosis development. In males and females, this CORT 
dose was sufficient to increase food intake and to maintain a higher bodyweight throughout the 
experiment. In addition, circulating circadian CORT levels at week 5 were 5-8 fold increased in the 
morning and 3-4 fold in the evening (data not shown).
sampling of circadian corticosterone, hormone, and lipid measurements
Plasma CORT was sampled before CORT administration (baseline), and after CORT administration at 
week 5 during the first light hour at 07.00 h, at 12.00 h, during the last light hour at 18.00 h, and three 
hours after the onset of the dark phase at 22.00 h. During the dark phase samples were collected in 
red light conditions. All CORT samples were obtained within 90 seconds from disturbing the cage, 
via tail incision, allowing the mouse to move freely on top of the home cage (26). Trunk blood was 
used to determine plasma CORT at the end of the experiment after CORT administration at week 17 
at 09.00 h and 18.00 h. Total plasma cholesterol, triglycerides, phospholipids, insulin and glucose 
were sampled after 4 hour-fast at baseline, week 5, 8 and 17 of the intervention. Body weight and 
food intake were measured weekly.
Plasma CORT levels were determined by radioimmunoassay (MP Biomedicals LCC, Orangeburg, 


















with enzymatic colorimetric reaction (Roche diagnostics GmbH, Mannheim; and Wako Pure 
Chemical Industries, respectively), plasma insulin was measured with an ELISA (Crystal Chem Inc., 
Downers Grove, IL, USA) and plasma glucose with a hexokinase method (Instruchemie, Delfzijl, The 
Netherlands). Homeostasis model index of insulin (HOMA-IR) was calculated by multiplying fasting 
insulin concentration (µU/ml) with fasting glucose (mmol/l), and dividing with 22.5 (27). 
lipoprotein profiling
Distribution of cholesterol over plasma lipoproteins was determined using fast protein liquid 
chromatography. Pooled plasma from each group were used and 50 µl of each pool was injected 
onto a Superpose 6 PC 3.2/30 column (Äkta System, Amersham Pharmacia Biotech, Piscataway, 
NJ) and eluted at a constant rate of 50 µl/min in PBS, 1 mM EDTA, pH 7.4. Fraction were collected 
and assayed for cholesterol as described above. 
Gene expression analysis in adipose tissue  
Total RNA was extracted from gonadal fat pads using the Nucleospin RNA II kit (Macherey-Nagel, 
Duren, Germany) according to manufacturer’s instructions. RNA quality of each sample was 
examined by the lab-on-a-chip method using Experion Std Sens analysis kit (Biorad, Hercules, 
CA) and RNA concentration of each sample was determined by Nanodrop technology (Thermo 
Scientific, Wilmington, USA). Then, total RNA was reverse-transcribed with iScript cDNA synthesis 
kit (1708891, Bio-Rad), and obtained cDNA was purified with Nucleospin Extract II kit (636973, 
Macherey-Nagel, Bioké). Real-time qPCR was performed on a CFX96 machine (Bio-Rad), the 
reaction mixture consisting of SYBR-Green Sensimix (QT615, GC Biotech), cDNA, primers (Biolegio, 
Nijmegen, The Netherlands), and nuclease-free water in a total reaction volume of 10 µl. mRNA 
values of each gene were normalized to mRNA levels of β2-microglobulin (β2m) and hypoxanthine 
ribosyltransferase (Hprt). Primer sequences are listed in supplementary table 1.
quantification of atherosclerosis
After 17 weeks of intervention, mice were killed by decapitation and the hearts were isolated. 
Hearts were fixed in phosphate-buffered 4% formaldehyde, dehydrated and embedded in paraffin. 
Cross-sections (5 µm) throughout the aortic root area were cut. 12 sections per mouse, stained 
with hematoxylin-phloxin-saffron for histological analysis, with 50 µm-intervals were used for 
atherosclerosis measurements. Lesions were categorized for severity according to the guidelines 
of the American Heart Association, adapted for mice (28, 29), as follows: type 0 (no lesions), types 
1 through 3 (early fatty streak-like lesions containing foam cells), and type 4 to 5 (advanced lesions 
containing foam cells in the media, presence of fibrosis, cholesterol clefts, mineralization, and/or 
necrosis). AIA 31240 antiserum (1:3000, Accurate Chemical and Scientific, Westbury, NY) was used 
to quantify macrophage content of the plaque as well as monocytes adhering to the endothelium. 
Lesion area, the macrophage area and the number of monocytes adhering to the endothelium 
were quantified using Image J software (National Institutes of Health).
serum macrophage colony-stimulating factor (M-csf) and anti-oxidized 
low-density lipoprotein (ox-ldl) antibodies measurements
Macrophage colony-stimulating factor (M-CSF) was measured using a mouse M-CSF Quantikine 
ELISA kit according to the manufacturer’s instructions (MMC00, R&D Systems Inc, Germany). An 
EIA/RIA high binding 96-well Costar plate (Corning Inc., Corning, NY, USA) was coated with ox-LDL 
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(7.5 µg/mL) in PBS. IgM and IgG2a antibodies against oxLDL in serum were measured using an ELISA 
Ig detection kit (Zymed Laboratories, San Francisco, CA, USA) according to the manufacturer’s 
protocol.
statististical analysis
Data are presented as means ± SEM. Statistical differences were calculated using Anova with Tukey’s 
post-hoc test, for multiple comparisons, except for plasma CORT measurements transient and 
continuous groups were compared with the control group individually per time point using an 
unpaired two tailed T-test, with GraphPad Prism, version 5.01. P<0.05 was considered as statistically 
significant.
results
cort treatment increases plasma cort concentrations and affects 
circadian rhythm 
Chronic administration of high doses of CORT in the drinking water (50 µg/ml) resulted in significant 
increases in plasma CORT levels at week 5 (Fig 1B) in both groups, compared to controls (transient 
group: 07.00 h 8-fold, 12.00 h 3-fold, 18.00 h 1-fold and 22.00 h 4-fold; continuous group: 07.00 h 
5-fold, 12.00 h 4-fold, 18.00 h 1-fold and 22.00 h 3-fold). At week 17 (Fig. 1C) there were no differences 
between groups at 09.00 h and 18.00 h. At the end of the experiment, thymus weight (Fig. 1D) was 
IgG2a antibodies against oxLDL in serum were measured using an ELISA Ig 




Data are presented as means ± SEM. Statistical differences were calculated using 
Anova with Tukey’s post-hoc test, for multiple comparisons, except for plasma 
CORT measurements transient and continuous groups were compared with the 
control group individually per time point using an unpaired two tailed T-test, with 
GraphPad Prism, version 5.01. P<0.05 was considered as statistically significant. 
 
RESULTS 
CORT treatment increases plasma CORT concentrations and affects circadian 
rhythm  
Chronic administration of high doses of CORT in the drinking water (50 µg/ml) 
resulted in significant increases in plasma CORT levels at week 5 (Fig 1B) in both 
groups, compared to controls (transient group: 07.00 h 8-fold, 12.00 h 3-fold, 18.00 h 
1-fold and 22.00 h 4-fold; continuous group: 07.00 h 5-fold, 12.00 h 4-fold, 18.00 h 1-
fold and 22.00 h 3-fold). At we k 17 (Fig. 1C) there were no differences between 
groups at 09.00 h and 18.00 h. At the end of the experiment, thymus weight (Fig. 1D) 
was not different between the three groups but adrenal weight (Fig. 1E) was 
significantly re uced in the continuously exposed gr up by -50%, in agreement with 
adrenal atrophy secondary to long-term exogenous GC exposure. 
Figure 1. Effect of transient 
and continuous CORT 
treatment on circadian plasma 
CORT levels in female 
E3L.CETP mice at baseline 
(A), week 5 (B) and week 17 
(C), as well as on thymus 
weight (D) and adrenal weight 
(E) at week 17 (Control group: 
white bars, transient group: 
grey bars and continuous 
group: black bars), Data are 
means ±  SEM (n=17-21),  *, 
#
P<0.05, **, ##P<0.01, 
###
P<0.0001, *versus control 
group and #transient group. 
 
figure 1. Effect of transient and continuous CORT treatment on circadian plasma CORT levels 
in female E3L.CETP mice at baseline (A), week 5 (B) and week 17 (C), as well as on thymus weight 
(D) and adrenal weight (E) at week 17 (Control group: white bars, transient group: grey bars 
and continuous group: black bars), Data are means ± SEM (n=17-21), *, #P<0.05, **, ##P<0.01, 


















not different between the three groups but adrenal weight (Fig. 1E) was significantly reduced in the 
continuously exposed group by -50%, in agreement with adrenal atrophy secondary to long-term 
exogenous GC exposure.
cort treatment affects food intake and bodyweight and induces long-
lasting changes in body composition and inflammation in adipose tissue
As expected, CORT treatment increased food intake of the transient and the continuous group 
during the first three weeks of the experiment after which the transient group returned to the level 
of the controls and food intake with continuous treatment remained elevated (Fig. 2A). This increase 
was accompanied by an increase in body weight (Fig. 2B) in both groups. After the discontinuation 
of CORT treatment, body weight decreased to the level of the controls. The continuously exposed 
group showed a continuous increase in body weight and maintained a higher body weight to the 
end of the experiment (Fig. 2B) compared to the other two groups. After 17 weeks, gonadal and 
subcutaneous fat pad weights (Fig. 2C and D), when compared to controls, were significantly 
increased by +35% and +31%, respectively, in the transient group, and by +140% and +110% in the 
continuous group. To evaluate whether the increased fat mass resulted in changes of inflammation in 
the fat pad, the mRNA expression of markers of the macrophage content (i.e. F4/80 and Cd68) and 
proinflammatory cytokines [Tumor necrosis factor α (Tnfα) and Interleukin-6 (Il-6)] in the gonadal 
fat pad were determined. As compared to control group, transient administration of CORT did not 
affect the expression of F4/80 (Fig. 2E) and CD68 (Fig. 2F), but decreased the expression levels of 
Tnfα (Fig. 2G) and Il-6 (Fig. 2H) in the long-term by -32% and -47%, respectively; while continuous 
administration of CORT increased the expression of F4/80 (Fig. 2E) and CD68 (Fig. 2F) by +58% 
and +70%, respectively, decreased the expression of Tnfα (Fig. 2G) by -26% and did not affect the 
expression of Il-6 (Fig. 2H). These data indicate although excess GC exposure increased fat mass 
which was accompanied with an increase in macrophage content, expression of proinflammatory 
cytokines in the adipose tissue was generally reduced.
cort treatment does not affect plasma lipids or cholesterol lipoprotein 
profile but increases plasma insulin and HoMa-ir 
Although both transient and continuous administration of CORT increased food intake to a 
certain extent, CORT treatment did not increase plasma levels of total cholesterol, triglycerides 
or phospholipids during the experimental period of 17 weeks (Table 1). Moreover, there were no 
differences between groups in the distribution of cholesterol over lipoproteins (Fig. 3A-C). Plasma 
levels of insulin and HOMA-IR, but not plasma glucose levels, were increased (Fig. 3 D-F) in the 
continuous group at week 17, reflecting GC-induced insulin resistance. 
transient and continuous cort treatment decrease atherosclerosis lesion 
area to a similar extent 
Remarkably, CORT treatment decreased total atherosclerotic lesion area equivalently in both 
transiently (-39%) and continuously (-39%) treated groups (Fig. 4A and B). Moreover, both transient 
and continuous groups showed similar trends towards a less severe lesion phenotype as compared to 
the control group (Fig. 4C), suggesting that CORT treatment reduces atherosclerosis development 
in a long-lasting manner. CORT treatment, neither transiently nor continuously, affected the 




figure 2. Effect of transient and continuous CORT treatment on food intake (A), body weight (B) 
(Control group: white circles, transient group: grey squares and continuous group: black triangles), 
gonadal fat (C) and subcutaneous fat (D) as % of the body weight mRNA expression of F4/80 (E), 
CD68 (F), Tnfα (G) and Il-6 (H) in the gonadal fat (Control group: white bars, transient group: grey 
bars and continuous group: black bars). Data are means ±SEM (n=17-21), Anova with Tukey’s post-hoc 
test, *, #P<0.05, **, ##P<0.001, ***, ###P<0.001 *versus control group and #versus transient group.
of CORT did reduce the macrophage content (-56%) of the plaque (Fig. 4D and F) as well as the 
macrophage content as percentage of the total plaque area (-52%) (Fig. 4G). A reduction of the 


















area (-27%, P=0.145) was observed in the transient group and but these reductions failed to reach 
statistical significance (Fig. 4F and G). Since uptake of oxidized LDL (ox-LDL) by macrophages to 
become foam cell plays an important role in the development and progression of atherosclerosis, 
we measured specific antibodies against ox-LDL in the circulation. As compared to control group, 
CORT treatment, neither transiently nor continuously, influenced the ox-LDL specific IgG2a and 
IgM level, indicating that CORT probably does not affect the ox-LDL level in circulation (Fig. 4H). 
Because macrophage proliferation and differentiation was shown to be linked to the atherosclerotic 
process (1), an essential factor regulating macrophage growth, macrophage colony stimulation 
factor (M-CSF) (30) was measured at the end of this experiment. However, no differences in the 
serum levels of M-CSF were detected among groups (Fig. 4I).
CORT treatment does not affect plasma lipids or cholesterol lipoprotein profile 
but increases plasma insulin and HOMA-IR  
Although both transient and continuous administration of CORT increased food 
intake to a certain extent, CORT treatment did not increase plasma levels of total 
cholesterol, triglycerides or phospholipids during the experimental period of 17 weeks 
(Table 1). Moreover, there were no differences between groups in the distribution of 
cholesterol over lipoproteins (Fig. 3A-C). Plasma levels of insulin and HOMA-IR, but 
not plasma glucose levels, were increased (Fig. 3 D-F) in the continuous group at 
week 17, reflecting GC-induced insulin resistance.  
Table 1. 
Effect of CORT treatment on fasting plasma lipids
Week Control Transient Continuous Control Transient Continuous Control Transient Continuous
0 10.0± 1.5 10.2 ± 2.3 10.2 ± 2.1 3.9 ± 1.1 4.3 ± 1.1 4.1 ± 1.4 3.6 ± 0.4 3.7 ± 0.6 3.5 ± 0.6
5 13.2 ± 1.8 14.0 ± 5.2 14.8 ± 4.2 4.6 ± 1.6 4.8 ± 2.3 4.5 ± 1.6 4.5 ± 0.6 4.5 ± 1.1 4.6 ± 1.0
8 13.4 ± 2.0 13.7 ± 3.9 12.4 ± 4.3 3.8 ± 1.5 4.0 ± 1.7 4.2 ± 0.9 4.5 ± 0.5 4.6 ± 0.8 4.2 ± 0.9
17 12.4 ± 2.8 10.2 ± 3.2 10.0 ± 3.0 3.2 ± 1.4 3.3 ± 1.0 2.9 ± 0.5 3.8 ± 0.9 3.4 ± 0.9 3.4 ± 0.7
Total cholesterol (mmol/l) Triglycerides (mmol/l) Phospholipids (mmol/l)
Data are means ± SEM (n=17-21), Anova with Tukey’s post-hoc test.  
 
Figure 3. Effect of transient and continuous CORT treatment on cholesterol distribution over 
lipoproteins fractioned by FPLC at baseline (A), week 5 (B) and 17 (C) (Control group: white circles, 
transient group: grey squares and continuous group: black triangles) and on plasma plasma insulin (D), 
plasma glucose (E) and HOMA-IR (F) (Control group: white bars, transient group: grey bars and 
continuous group: black bars) on week 17. Data are means ± SEM (n=17-21), Anova with Tukey’s 
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figure 3. Effect of transient and continuous CORT treatment on cholesterol distribution over 
lipoproteins fractioned by FPLC at baseline (A), week 5 (B) and 17 (C) (Control group: white circles, 
transient group: grey squares and continuous group: black triangles) and on plasma plasma 
insulin (D), plasma glucose (E) and HOMA-IR (F) (Control group: white bars, transient group: grey 
bars and continuous group: black bars) on week 17. Data are means ± SEM (n=17-21), Anova with 
Tukey’s post-hoc test, **, ###P<0.001, *versus control group and #versus transient group.
table 1. Effect of CORT treatment on fasting plasma lipid
Week
Total cholesterol (mmol/) Triglycerides (mmol/l) Phospholipids (mmol/l)
Control Transient Continuous Control Transient Continuous Control Transient Continuous
0 10.0±1.5 10.2±2.3 10.2±2.1 3.9±1.1 4.3±1.1 4.1±1.4 3.6±0.4 3.7±0.6 3.5±0.6
5 13.2±1.8 14.0±5.2 14.8±4.2 4.6±1.6 4.8±2.3 4.5±1.6 4.5±0.6 4.5±1.1 4.6±1.0
8 13.4±2.0 13.7±3.9 1 .4± 3 3.8±1.5 4.0±1.7 4.2±0.9 4.5±0.5 4.6±0.8 4.2± .9
17 12.4±2.8 10.2±3.2 10.0±3.0 3.2±1.4 3.3±1.0 2.9±0.5 3.8±0.9 3.4±0.9 3.4±0.7





Figure 4. Effect of transient and continuous CORT treatment on atherosclerosis development: 
representative HPS-stained pictures of lesions (A), lesion area (B), lesion type as % of the total lesion 
(C), representative pictures of monocyte/macrophage staining (adhering monocytes shown by arrows) 
(D), adhering monocytes per segment (E), macrophage content of the plaque (F) and macrophages as 
% of the lesion area (G). Serum anti-ox-LDL specific antibodies (H) and serum M-CSF (I) were 
measured on week 17.  (Control group: white bars, transient group: grey bars and continuous group: 
black bars). Data are means ± SEM (n=17-21), Anova with Tukey’s post-hoc test, *#P<0.05, **P<0.01, 
*versus control group and #versus transient group. 
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bars and continuous group: black bars). Data are means ± SEM (n=17-21)  Anova with Tukey’s 



















This study demonstrates for the first time that CORT treatment resulting in increased plasma CORT 
concentrations decreases atherosclerotic plaque formation in mice with human-like lipoprotein 
metabolism, without affecting either plasma lipid levels or lipoprotein profiles. Interestingly, 
inhibition of atherogenesis was found both in transiently and continuously exposed animals, whereas 
continuous treatment with CORT also decreased macrophage content of the plaque despite the 
normalization of the body weight. In addition, CORT treatment resulted in long-lasting changes in 
body fat content, which were still present even 12 weeks after abrogation of CORT. This indicates that 
increased CORT exposure per se has beneficial, long-lasting effects on atherosclerosis, but negatively 
affects body fat distribution and insulin sensitivity, by promoting fat accumulation in the long-term. 
The concentration of glucocorticoids (GCs) attained in our experiments is higher than 
under stress state but well comparable to patients with severe Cushing’s syndrome, where cortisol 
secretion was 7 times higher that in healthy controls and circulation cortisol concentrations was 
3-5 times higher (31). 
Increased plasma CORT levels were easily induced non-invasively using CORT in the 
drinking water. CORT affected circadian GC rhythm by reducing the degree of variation in plasma 
concentrations. The human clinical equivalent of chronic hypercortisolemia, Cushing’s syndrome 
(CS), is characterized by a blunted or even complete loss of diurnal rhythm (3). In our model we 
re-capitulate some of these key temporal aspects of CS: although a chronic high circulating cortisol 
levels is a key aspect of CS, the most reliable measure for diagnosis is very high late night (i.e. 22:00 
–24:00 h) plasma cortisol (3). Our high- CORT animals parallel these aspects of the syndrome, with 
both high baseline levels of CORT (200 ng/ml), as well as a peak in CORT at the end of the night 
(rather than at the beginning). Moreover, the continuously exposed group displayed reduced 
adrenal sizes, in agreement with adrenal atrophy, secondary to the long-term exogenous CORT 
administration despite normal plasma CORT levels found at the end of the experiment. This might 
be explained by increased metabolism of CORT as well as by other pharmacokinetic adaptations 
like increased clearance and increased distribution volume as a result of increased adipose tissue. 
Plasma lipid levels were not affected by transient nor continuous CORT treatment. This is 
interesting particularly in the case of plasma values of total cholesterol, VLDL-cholesterol and 
VLDL-triglycerides since these are well known risk factors for the development of atherosclerosis. 
In fact, cholesterol exposure generally is a good predictor of atherosclerosis development in 
E3L.CETP mice (Princen and Rensen, unpublished observations). Moreover, CORT exposure did 
not affect lipoprotein profiles. In previous studies, mice were subjected to chronic stress, which 
causes a complex of endocrine changes, including high CORT levels. These studies have reported 
inconsistent effects on plasma cholesterol levels, which were increased (15), decreased (16), or 
not reported (14). These studies used ApoE-deficient mice in which the ApoE- deficiency causes 
severe accumulation of cholesterol in macrophages resulting in a high pro-inflammatory state, 
which could explain the differences observed in atherosclerosis development between our low 
grade inflammation model of E3L.CETP mice fed a low amount of dietary cholesterol (twice human 
daily intake) (32, 33). In addition, the use of chronic stress to increase endogenous GCs in previous 
models will also induce other complex endocrine and metabolic changes (17) that may also affect 
atherosclerosis development. Humans with high GCs also have inconsistent cholesterol levels. In 
the literature, the prevalence of hyperlipidemia in patients with CS varies from 38% to 71% (34). A 
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study by Mancini et al (2004) has shown that hyperlipidemia occurs less frequently than the other 
metabolic complications of CS and that it was not correlated to the degree of hypercortisolism 
or duration of the disease (35). However, the causative role of cortisol excess for hyperlipidemia 
has not been extensively described in the literature and the findings are, like the animal data, 
controversial. In some study populations, the prevalence of hypertriglyceridemia was even lower 
than in BMI-matched controls (36). 
Intriguingly, CORT treatment reduced atherosclerotic lesion area, and tended to decrease 
lesion severity, to a similar extent in transiently vs continuously exposed mice. This suggests 
that GCs are able to induce long-term effects in the preliminary processes of atherosclerotic 
plaque formation. It is tempting to speculate on possible underlying mechanistic explanations 
for this phenomenon. One possibility is the induction by increased GC exposure of epigenetic 
mechanisms, like chromatin remodeling and histone modifications (37). These alterations have been 
demonstrated in the context of chronic CORT (38), and may lead to long lasting suppression of or 
changes in macrophage function. Extensive documentation supports a crucial role for macrophages 
in the initiation of atherosclerosis by entering the vessel wall, taking up oxidized LDL (ox-LDL) (1, 
2) and transforming into foam cells that produce a variety of cytokines further driving the process 
of the plaque formation, as well as macrophage proliferation and differentiation (39, 40). In the 
present study, transient and continuous CORT treatment did not affect the plasma ox-LDL level, 
albeit that continuous CORT treatment significantly reduced the macrophage content of the 
plaque, and a similar trend was also observed in the transiently exposed group. GCs were shown 
to decrease the development of atherosclerosis by reducing the monocyte recruitment (41-43), 
macrophage foam cell formation (44), macrophage growth, as well as macrophage inflammatory 
action to produce pro-inflammatory cytokines (45). In this study, no differences were observed in the 
number of monocytes adhering to endothelium between the groups. It is plausible that GCs excess 
inhibits macrophage growth instead of monocyte recruitment as GCs inhibit macrophage colony 
stimulating factor (M-CSF)-induced macrophage differentiation in vitro (45). Although, we did not 
detect any differences in serum M-CSF level between groups, it should be realized that M-CSF is a 
general marker for macrophage growth, and the systemic concentration in plasma may not reflect 
the local macrophage growth in the vessel. Additionally, GCs can also inhibit macrophage growth 
by suppressing the granulocyte/macrophage colony-stimulating factor (GM-CSF) production in 
isolated macrophages (46), confirming that GCs might target the macrophage, the major cellular 
CORT target, thereby attenuating macrophage proliferation and differentiation, and thus inhibiting 
atherosclerotic plaque formation. 
In humans, increased GC exposure, like in patients with CS, is associated with the metabolic 
syndrome and cardiovascular disease, even after long-term successful correction of GC excess (6, 
47, 48). Carotid intima media thickness (IMT) is increased and vessel wall plaques are more common 
in patients with CS (36, 49, 50). Indeed, CS patients have abnormal fat distribution and suffer from 
disturbed coagulation and osteoporosis. Although, it is documented that bone mineral density fully 
recovers after normalization of cortisol levels, other features, like the adverse metabolic profile 
and the hypercoagulable state, do not completely resolve (51, 52). The causal relation, however, 
between the episode of cortisol overexposure and long-term changes in the development of 
cardiovascular diseases is not established and is difficult to assess in humans because of the rarity 
and heterogeneity of CS. In agreement, in our mouse model CORT also stimulated the development 


















body weight, insulin concentrations, and altered body composition. High CORT levels are known 
to stimulate voluntary food intake dose-dependently (53-55). GCs are also known to induce insulin 
resistance (48). Moreover, insulin and CORT synergistically promote redistribution of energy 
storage in favor of increased fat tissue (56). The changes in body weight were accompanied by a 
significant increase in both gonadal and subcutaneous fat mass in continuous group and, remarkably 
after 12 weeks of wash out, in transiently exposed group as well. Chronically administered GC 
facilitates an increase of fat mass in mice (25, 57). In humans, increased exposure to cortisol (being 
either endogenous CS or exogenous corticosteroids) induces increased total body fat (58), and is 
specifically characterized by a redistribution of adipose tissue from peripheral to central sites of the 
body, mainly in the truncal region and visceral depots In the human equivalent of severe chronic 
stress, CS, the prevalence of the metabolic syndrome is increased (47, 48), and intriguingly, after 
remission, these patients still have increased waist circumference (36, 60) and higher visceral fat 
mass without an effect on the body mass index (61), and their cardiovascular risk remains increased. 
Adipose tissue macrophages are the primary source of the proinflammatory cytokines, and the 
macrophage content of adipose tissue has been shown to correlate positively with adiposity 
(62). In the present study, although excess GC exposure increased fat mass and induced obesity 
which was accompanied with an increase in macrophage content, inflammation in the adipose 
tissue was not elevated. Moreover, after abrogation of CORT treatment, the macrophage content 
in the adipose tissue was normalized and the reduction of inflammation was persisted in the 
long-term despite of the presence of a persistent increase in fat mass. CORT treatment induces 
prolonged, complex changes in the adipose tissue that reflect both the adverse metabolic effects 
of glucocorticoids by increasing the adiposity, and the anti-inflammatory capacity by reducing the 
expression of the proinflammatory molecules in the macrophages. Therefore, we cannot exclude 
that the protective effects of CORT treatment on atherosclerosis development can, at least partly, 
be explained by decreased release of cytokines from adipose tissue. It is well possible that at high 
dose, the anti-inflammatory effects of GCs attenuate potentially adverse metabolic influences. 
In clinical practice, this means that GC schemes as used for anti-inflammatory indications might 
benefit from adjustments towards a higher dose for a shorter period of time (or even as a few ‘high 
dose ‘pulses’ as is used in clinical practice with methyprednisolone instead of lower dosages for a 
prolonged period of time.
In conclusion, increased CORT exposure in mice with a human like lipoprotein metabolism has 
beneficial, long-lasting effects on atherosclerosis, despite negatively affecting body fat distribution 
and insulin sensitivity by promoting fat accumulation in the long term. This indicates that the 
increased atherosclerosis observed in the human in states of GC excess may not be related to 
cortisol per se, but may be the result of complex effects of cortisol on the endothelium and/or 
coagulation. The effects of GC excess, therefore, are multiple, and dependent on many factors, 





supplemental table 1. Primer sequences used for RT-qPCR







β2m, β2-microglobulin; Hprt, hypoxanthine ribosyltransferase; IL-6, Interleukin-6; Tnfα, Tumor necrosis factor α.
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Today’s Western society and work promotes a sedentary lifestyle, which from an evolutionary 
perspective, is a relatively recent development. This, coupled with the high availability of foods 
with high caloric content in Western cultures, superimposed on dated genotypes has given rise to 
the pandemic of obesity with its related increase in prevalence of the metabolic syndrome (MetS), 
type 2 diabetes (T2D) and cardiovascular diseases (CVD). At the same time, the perceived social 
stress in everyday’s society has increased (1). Furthermore, lack of sleep and sleep disturbances 
have become increasingly common and today we are, even voluntarily, sleep restricting ourselves 
and sleep significantly less than thirty years ago (2).
The metabolic effects of perceived stress are mediated by glucocorticoids (GCs) that are 
secreted by the adrenals as a result of stressor-induced activation of the hypothalmus-pituitary-
adrenal (HPA) axis. The effects of GCs include recruitment of energy storages from fat and muscle 
(3, 4), but also central activation with adjustment of feeding behavior resulting in an increase in 
the intake of palatable foods to compensate for the catabolic effects (loss of energy) in peripheral 
tissues. These metabolic adaptations occur during the stressful event, with the purpose to be 
enable the evolutionary “fight or flight” response (5). It is therefore not surprising that, in the 
presence of such an evolutionary ‘pressure’ of stress, the consumption of “comfort food” as well as 
“emotional eating” has increased (6), further facilitating the development of obesity, the MetS, T2D 
and CVD (7). Epidemiological data show a clear association between increased plasma levels of the 
GC cortisol and CVD and obesity, but animal models of the MetS are inconclusive with respect to 
whether the HPA axis is activated or not. Thus, up till now, it was unknown if, and to what extent an 
increased activity of the HPA axis plays a pathogenic role in the development of the MetS, and vice 
versa, whether development of MetS leads to increased activity of the HPA axis, if there would be 
a role of development of specific features of the MetS, i.e. obesity, on the activity of the HPA axis.
In this thesis we have chosen to evaluate both whether baseline, non-stressed, activity of the 
HPA axis is affected during the development of obesity, and vice versa, to what extent a period of 
exposure to increased endogenous GC levels would affect specific features of the MetS. The major 
conclusions and implications of our findings will be discussed in this chapter.
impact of the development of obesity on baseline, non-stressed, activity of 
the Hpa axis
As stated above, overweight and obesity have become prominent global health problems and are 
no longer a health issue that only affects adults but also children and adolescents. Overweight and 
obesity are often accompanied by other metabolic abnormalities, such as dyslipidemia and insulin 
resistance, that can be clustered to define a clinical syndrome that is associated with increased 
cardiovascular morbidity and mortality: the MetS (8).
The basal activity of the HPA axis, i.e. not induced by stress, has been reported only in a 
limited number of studies in obese individuals (9-12), and these results have been inconclusive. 
A key issue in this respect is the difficulty to assess the activity of the HPA axis in conditions were 
individuals are exposed to social stress, as is present in everyday life. In this respect, animal models 
can be very useful, since under laboratory conditions, in principle it is possible to control for many 
potential stressors that might affect the outcome. 
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In chapter 2 we critically evaluated the current literature available reporting the effects of high 
fat diet (HFD) on the basal, non-stressed, activity of the HPA axis in mice by performing a structured, 
and systematic review of all the available literature on this topic using the main medical databases. 
We included only original mouse studies that reported parameters reflecting the activity of the HPA 
axis after a prolonged period of HFD feeding, because there is extensive documentation that HFD 
feeding per se is able to induce obesity and insulin resistance, especially in wild-type C57Bl/6 male 
mice (13-16). For inclusion in the review, at least one basal corticosterone (CORT) measurement and 
a proper control group was required. Studies with adrenalectomized mice, transgenic animals only, 
HFD for less than two weeks, or other interventions besides the HFD, were excluded, as they do 
not represent normal physiology. In addition, we excluded studies with an insufficient duration of 
exposure to the HFD to be able to induce significant features of the MetS. We found twenty studies 
that fulfilled our stringent inclusion criteria, but surprisingly, in only five studies the evaluation 
of the HPA axis was the primary research question. Plasma CORT levels in these twenty studies 
were found to be increased, unchanged, or even decreased. Additional parameters reflecting the 
activity of the HPA axis, such as 11β-dehydrogenase (11β-HSD-1) expression in peripheral tissues 
such as liver and fat, and corticotropin releasing hormone (CRH) and/or glucocrticoid receptor 
(GR) expression in the central nervous system, were evaluated only in five out of these 20 studies, 
and these data were also not consistent.
Importantly, there were many differences between the studies that precluded a reliable 
comparison of the effects of HFD on the HPA axis between studies. For instance, the relative 
energy contribution of fat in the diet varied between 32-65%, and different mouse strains were 
used, resulting in a large variation in weight gain. In addition, there were different housing and 
sampling conditions. All these factors are known to differentially affect the activity of the HPA 
axis, and therefore, all can contribute to the different results observed in the studies. Most 
importantly, different housing conditions, e.g. group-wise vs. individual housing, has shown to 
dramatically affect both basal and stress-induced HPA axis activity, as in a group a social order is 
about to form with dominant and subordinate individuals, that display different coping strategies 
when faced with social stress (17, 18). In addition, the majority of the studies failed to report on 
the sampling conditions for CORT (especially whether stress-free sampling was performed: at 
best, some reported on the elapsed time between opening of the cage and sample collection). 
Some studies even reported the use of anesthesia before sampling, which, by definition, requires 
more handling of the animal, which has an additional effect (besides the anesthetic per se) on 
the central nervous system.
Thus, the systematic review demonstrated that the effects of HFD on the basal activity of the 
HPA-axis, and its contribution in the propensity to become obese and develop other manifestations 
of the MetS on a HFD, remained unclear. For a proper and reliable evaluation of the basal activity 
of the HPA axis, we reasoned that an appropriate study design is therefore a prerequisite. We 
proposed that such an appropriate design should, at least, take the following factors into account: 
1) choice of mouse strain (genetically modified or not, DIO-resistant or not, resistant to stress or 
not), 2) duration and content of the diet, 3) standardization of housing conditions with a possibility 
to acclimate in advance, 4) proper methods for stress free sampling of CORT, and 5) the timing of 
the sampling to reflect circadian rhythmicity.
Therefore, in chapter 3 we applied the most appropriate study design as proposed in 




















the HPA axis, both peripherally and centrally, in C57BL/6 mice with previous extensive available 
documentation with respect to the development of obesity and insulin resistance when fed a HFD 
(12-15). We measured plasma CORT using a stress-free sampling method both at the circadian nadir 
and at the circadian peak (in the evening). HFD decreased diurnal peak CORT already at the first 
week of HFD feeding and the levels remained significantly lower when compared to controls up 
to twelve weeks (the end of the experiment). This finding is in line with a recent study reporting 
decreased basal plasma CORT values in a similar study design, but with a shorter duration of the diet 
(19). Furthermore, we observed that HFD induced complex changes in CRH and GR mRNA expression 
in the central nervous system areas responsible for feeding behavior and limbic functions, namely 
the paraventricular nucleus (PVN) of the hypothalamus, the amygdala, and hippocampus. In the 
peripheral white adipose tissues, HFD induced a profound down regulation of 11β-HSD-1 enzyme 
mRNA. Since this enzyme converts cortisone and 11-dehydrocorticosterone into their active forms 
cortisol and CORT, this reflects decreased CORT exposure at the tissue level. In agreement with 
these findings, we found no changes in 11β-HSD-2 enzyme mRNA expression, which converts 
cortisol and CORT into their inactive forms, thus leading to a reduced net effect of CORT exposure 
in the tissue level. 
figure 1. Tentative model of the effect of HFD on the HPA axis activity. See text for explanation
a possibility to acclimate in advance, 4) proper methods for stress free sampling of 
CORT, and 5) the timing of the sampling to reflect circadian rhythmicity. 
Therefore, in chapter 3 we applied the most appropriate study design as proposed in 
chapter 2. In this study, the aim was to document the effects of HFD on the basal 
activity of the HPA axis, both peripherally and centrally, in C57BL/6 mice with 
previous extensive available documentation with respect to the development of 
obesity and insulin resistance when fed a HFD (12-15). We measured plasma CORT 
using a stress-free sampling method both at the circadian nadir and at the circadian 
peak (in the evening). HFD decreased diurnal peak CORT already at the first week of 
HFD feeding and the levels remained significantly lower when compared to controls 
up to twelve weeks (the end of the experiment). This finding is in line with a recent 
study reporting decreased basal plasma CORT values in a similar study design, but 
with a shorter duration of the diet (19). Furthermore, we observed that HFD induced 
complex changes in CRH and GR mRNA expr ssion i  the central nervous system 
areas responsible for feeding behavior and limbic functions, namely the 
paraventricular nucleus (PVN) of the hypothalamus, the amygdala, and hippocampus. 
In the perip eral whit  adi ose tissues, FD induced a pr found down regulation of 
11β-HSD-1 enzyme mRNA. Since this enzyme converts cortisone and 11-
dehydrocorticosterone into their active forms cortisol and CORT, this reflects 
decreased CORT exposure at the tissue le l. In agreement with these findings, we 
found no changes in 11β-HSD-2 enzyme mRNA expression, which converts cortisol 
and CORT into their inactive forms, thus leading to a reduced net effect of CORT 
exposure in the tissue level.  
Figure 1. Tentative model of the 
effect of HFD on the HPA axis 









The results found in the first two studies, first of all indicate that a proper study design is 
crucial for reliably evaluating the HPA axis. In addition, it appeared that the development of obesity 
leads to secondary adaptive responses of the HPA axis that cannot be interpreted by just measuring 
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circulating CORT concentrations only. Fundamental in this respect is the fact that obesity per se 
increases body fat and thus the distribution volume for CORT (which is fat soluble), and therefore 
decreases circulating CORT levels and stimulates central activation of the HPA axis as discussed in 
the introduction. However, the net result of HPA axis activation in obesity is complex and is also 
influenced by central and peripheral interactions with orexigenic hormones (like leptin) (20-24), by 
changes in adrenal sensitivity for adrenocorticotropic hormone (ACTH) (25, 26), and by changes in 
enzymatic (de)activation of CORT in peripheral tissues (by the 11β-HSD type 1 and 2) (27, 28). Thus, 
it can be argued that the adaptation of the HPA axis to the HFD, at least in part, is secondary to 
the increasing body weight. Pair-feeding (29), in which less HFD is given to a caloric amount that 
is consumed in chow-fed animals, provides an experimental set up that eliminates the effect of 
energy intake and possible subsequent weight gain, thus allowing to observe the “true” effect of 
HFD on the HPA axis parameters. These results, however, could be hampered by the stress induced 
by the reduced feeding (30), and if so, periods of hunger experienced by the pair-fed group would 
also no longer represent a stress-free model. 
The present study was performed in adult mice naive for HFD. Therefore the results should 
be interpreted with caution and cannot simply be extrapolated to neonates, pups, adolescent mice, 
or to the offspring of HFD-fed mothers. Previous studies have shown that maternal exposure to 
HFD during pregnancy and postnatally, even without developing obesity, resulted into increased 
weight and insulin as well as leptin resistance of the offspring, both in adolescence and adulthood 
(31-36). Exposure to maternal HFD resulted in increased plasma CORT in rat pups (37) but weaning 
of pups to HFD decreased 11β-HSD-1 activity in the liver and adipose tissues (38). Furthermore, 
maternal exposure to HFD led to changes in melanocortin expression and disturbances of the 
pro-opiomelanocortin (POMC) system in the fetal offspring of nonhuman primates (39). Finally, 
some studies have also demonstrated altered stress-induced responsiveness of the HPA axis: 
adult offspring of HFD-fed rats exhibited an increased reactivity to acute stress (40) and neonatal 
pups from HFD-fed mothers showed a decreased response to stress whereas in adulthood stress 
responsiveness was increased (41). These findings demonstrate that HFD exposure may result 
in multiple effects on both basal and stimulated activity of the HPA axis, and that these effects 
are dependent on the duration of the exposure as well as on the timing (age) of the exposure. 
Therefore, it should be noted that the results obtained from different studies reflect the particular 
experimental set up. 
Thus, HFD, which is abundantly available in today’s society, induces complex changes in the 
diurnal regulation of various components of the HPA axis. This is of paramount importance because 
activation of the HPA axis in the central nervous system, for instance, not only affects metabolic 
‘sensing’ but is also a key modulator for the limbic system, facilitating learning, memory formation 
and retrieval (42), thereby affecting individual (psychological) well being. 
For future studies, it would be interesting to investigate whether the effects of HFD on both 
the basal activity of the HPA axis and stress responsiveness are reversible. This is of importance 
since it has been shown that obesity is a risk factor for Alzheimer’s disease (43) and depression 
(44), both of which are also associated with alterations of the HPA axis. Futher more, there is no 
awereness on whether development of obesity leads to secondary adaptive changes of the HPA 
axis which may, in turn, lead to altered set points of hormone release and tissue sensitivity as has 




















the effects of a period of endogenous Gc excess on the Mets and 
atherosclerosis 
The fundamental question that arises from our previous observations is whether the HPA axis is 
able to adapt sufficiently during the development of obesity in the presence of chronic (social) 
stress. From an evolutionary point of view, social stress is considered to be a chronic challenge, as 
cortisol, secreted during stress response, promotes feeding behavior (46) to compensate for the 
energy loss that takes place during the “fight or flight” responses. However, in the given context, 
such an energy loss might never take place and thus the individual, driven by the evolutionary 
drive orchestrated by the central nervous system, only further promotes a positive energy balance 
resulting in weight gain and insulin resistance, continuing the vicious cycle. 
GCs are also potent anti-inflammatory agents that are widely used for their immunosuppressive 
properties but they also play a major role in glucose, lipid, and protein metabolism (47-49). In 
humans, an increased activity of the HPA axis has been linked to the development of the MetS (50). 
In addition, manipulation of cortisol exposure at the tissue level in mice, through stimulation or 
abrogation of 11β-HSD-1 and 11β-HSD-2 activity can increase, or regress, visceral fat accumulation, 
as well as other features of the MetS (27, 28). However, as discussed extensively in the previous 
paragraphs, these associations should be interpreted with caution and do not prove causality. In 
agreement, however, with these observations is the rare clinical syndrome of Cushing’s syndrome 
(CS). CS in the human is the result of prolonged excessive exposure to GCs (in the majority of cases 
caused by ACTH secreting pituitary adenoma with subsequent adrenal overstimulation) and is 
typically associated with an increased prevalence of the MetS, albeit with a specific phenotype, 
with increased cardiovascular morbidity and mortality (51). Intriguingly, patients treated for CS 
remain at increased cardiovascular risk, even after long-term successful correction of GC excess 
(52). Although this is the best human model representing a (transient) period of GC excess, in the 
absence of other pathology or auto-immunity, the causal relation between the episode of cortisol 
overexposure and long-term changes in cardiovascular risk factors is not established and is difficult 
to assess because of the rarity and heterogeneity of CS in humans. 
Therefore, in chapter 4 we used a mouse model that has previous extensive documentation of 
development of certain features of the MetS, in this case obesity and insulin resistance, when exposed 
to HFD (13-16). In that study, we aimed to identify factors that modulate metabolic recovery from a 
period of overexposure to GCs. Male C57Bl/6J mice, fed a low fat diet (LFD) or HFD, received CORT 
or vehicle in the drinking water for 4 wks, followed by a washout period of 8 wks. CORT treatment 
increased plasma CORT, food intake and plasma insulin and lipids in both diets. Abrogation of CORT 
treatment normalized plasma CORT levels diet-dependently: mice fed LFD had normal circadian 
plasma CORT levels already after 4 weeks of washout whereas the CORT peak was still decreased 
in the HFD-fed mice when compared to their respective controls. Food intake and body weight 
normalized after removal of the CORT treatment. Intriguingly, at week 12 (i.e. after an eight weeks 
washout period and 6 weeks after normalization of body weight in the HFD-fed mice), plasma insulin 
levels were still significantly higher in CORT-treated mice on both diets, and HFD-fed CORT-treated 
mice had persistently decreased lean body mass and increased fat mass. Thus, in mice, a period 
of CORT excess induced long-lasting increase in plasma insulin levels and fat mass. However, the 
changes in body composition were present only in the presence of HFD. Interestingly, the recovery 
of the HPA axis, when measured as circadian plasma CORT levels, occurred earlier with LFD.
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This can be of importance because CS patients, like all humans exposed to chronic stress, are 
likely to make dietary choices directed towards highly palatable foods (53) which would negatively 
affect the recovery of the HPA axis after treatment. In addition, it has been shown that HFD reduces 
the adrenal cortex sensitivity to ACTH (25, 26) and, therefore, could aggravate the withdrawal 
from, at least, synthetic steroids and postpone the recovery of endogenous adrenal cortisol 
production. Furthermore, slower recovery of the HPA axis secondary to HFD could also contribute 
to the psychopathologies as observed in CS patients even after long term correction from the 
supraphysiological cortisol levels (54). These observations are in complete agreement with the 
evolutionary drive of the stress response and points at a crucial role for dietary composition in 
the development of the MetS in conditions with periodic excessive GC exposure, like is the case 
in patients treated for CS, but possibly also in the general population exposed to chronic stress.
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Figure 3. Individual experiencing 
chronic stress, like in CS, can, 
dependent on genetic/epigenetic 
predisposition, priming life events 
and individual coping styles, develop 
MetS and increase risk for CVD. 
Certain effects such as altered body 
composiotion, decreased insulin 
sensitivity and cardiovascular 









In chapter 4 we chose to give CORT in the drinking water as opposed to 
supplementing the mice with e.g. subcutaneous (sc) CORT pellets. As expected, this 
non-invasive supplementation of CORT via the drinking water allowed the 
figure 2. Individual experiencing chronic stress, like in CS, can, dependent on genetic/
epigenetic predisposition, priming life events and individual coping styles, develop MetS and 
increase risk for CVD. Certain effects such as altered body composiotion, decreased insulin 
sensitivity and cardiovascular mortality can prevail long even after remission.
In chapter 4 we chose to give CORT in the drinking water as opposed to supplementing the mice 
with e.g. subcutaneous (sc) CORT pellets. As expected, this non-invasive supplementation of CORT 
via the drinking water allowed the preservation of a certain degree of variability of circulating plasma 




















studies that have used sc pellets for CORT supplementing resulted in abolishment of the ultradian 
rhythm, which restored after removal of the pellets in intact rats (55). In patients with CS, the diurnal 
variation in cortisol secretion is abolished in most patients. Cortisol secretion in these patients 
was further characterized by markedly amplified total daily hormone secretion secondary to an 
approximately 7-fold higher basal secretion rate, and increased secretory burst mass (ACTH and 
cortisol) and frequency (cortisol) (56). To be able to distinct between the preserved rhythm and 
continuously increased CORT levels and their long term effects, both methods of supplementation 
should be compared in one experiment. In the studies performed in chapter 4, the mice were given 
LFD or HFD with or without CORT treatment and no choice of diet was applied. We know, however, 
that GCs direct the choice of food toward more palatable, high energy foods rich in fat and sugar 
(53). Therefore, to truly estimate the effects of CORT treatment on body weight and composition 
as well as on insulin resistance, a study would be needed where choice of food is available during 
the tretament and washout. 
In chapter 5 we investigated the effects of a period of high GC exposure vs continuous 
overexposure on the development of atherosclerosis in a mouse model with human-like lipoprotein 
metabolism, namely ApoE*3-Leiden.CETP (E3L.CETP ) female mice on a C57Bl/6J backtground. 
These mice represent a well-established model for the development of atherosclerosis when fed 
a cholesterol-rich diet (57). We induced high plasma CORT levels by adding CORT to the drinking 
water for either 5 wks (transient high exposure) or 17 wks (continuous high exposure). We found 
that CORT treatment increased body weight and food intake for the duration of the treatment and 
increased white adipose tissue weight in both treatment groups in the long-term. Both transient 
and continuous CORT treatment decreased total atherosclerotic lesion area to the same extent, 
without reducing plasma cholesterol levels. This was accompanied by a decrease in macrophage 
content of the plaque to a similar extent after both treatments. 
The fact that CORT treatment reduced atherosclerotic lesion area, and tended to decrease 
lesion severity to a similar extent in transiently vs continuously exposed mice suggests that GCs are 
able to induce long-term effects in the preliminary processes of atherosclerotic plaque formation 
such as inhibiting the uptake of oxidized low-density lipoproteins (LDL) by macrophages (58, 59). 
Subsequent transformation of macrophages into foam cells that produce a variety of cytokines will 
further accelerate the process of plaque formation (60, 61) as well as the regulation of the expression 
of adhesion molecules in the vascular endothelium, thereby restricting the number of neutrophils 
entering the vessel wall (62, 63). The macrophage content of the plaque was significantly reduced 
in the continuously exposed group, and a similar trend was also observed in the transiently exposed 
group. We did not observe any differences in the number of monocytes adhering to endothelium 
between the groups. More likely, CORT excess stimulated the inhibition of macrophage growth 
and/or maturation instead of monocyte recruitment. GCs have been shown to inhibit oxidized 
LDL-induced macrophage growth by suppression of granulocyte/macrophage colony-stimulating 
factor (M-CSF) (64), thereby inhibiting atherosclerotic plaque formation. 
It is difficult to compare our data with the limited data available from other mouse studies 
that evaluated the effects of GC on atherosclerosis. For instance, many of these studies used 
chronic stress as a model to increase endogenous GC but this will also induce other endocrine and 
metabolic changes (65) that may affect atherosclerosis development. Other studies used ApoE-
deficient mice that harbor a different pro-inflammatory state (66) in contrast to the low-grade 
inflammation model of E3L.CETP mice used in our study (67, 68).
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Whereas our observations in mice in chapter 4, i.e. insulin resistance, dyslipidemia and 
changes in body composition, are in a good agreement with the phenotype found in CS patients 
(49, 69-71), our findings in chapter 5 are striking because in humans, increased GC secretion, like 
in patients with CS, is associated with CVD, although the exact role of GC in the development of 
atherosclerosis is not yet clearly established. Intriguingly, patients with CS remain at increased 
CVD risk, even after long-term successful correction of GC excess (52). Although limited, data 
in patients with CS indicate that carotic intima media thickness (IMT) is increased and vessel wall 
plaques are more common (69, 72, 73). Apart from atherosclerosis, CS patients have abnormal fat 
distribution, coagulopathy, and osteoporosis. Recent data indicate that remission of CS improved 
some but not all cardiovascular risk markers (74, 75). 
Thus, increased CORT exposure in mice with human-like lipoprotein metabolism has long-
lasting, beneficial effects on atherosclerosis, although it negatively affects body fat distribution 
and insulin sensitivity, by promoting fat accumulation in the long-term. This indicates that the 
increased atherosclerosis observed in humans in states of GC excess may not be related to cortisol 
per se, but may be the result of circulating GC (endogenous or synthetic) concentrations and of 
complex effects of GCs on the endothelium and/or coagulation (74, 75), and, finally, of epigenetic 
mechanisms (76, 77).
The results in chapter 5 were obtained in adult mice and therefore age can be a factor 
determining the outcome. In the present study, the mice were allowed to age to adulthood without 
developing atherosclerosis and then were given a cholesterol trigger to start the development 
of the atherosclerotic plaques simultaneoulsy with the CORT treatment. Therefore, the timing 
of the treatment is fundamentally directed to the initiation of the atherosclerosis development. 
However, in humans the development of the plaques and thickening of the intima start already 
earlier in life (adolescence) (78) and thus the period of high GC exposure, like seen in CS, takes 
place in the later stages of the development of the atheroslerosis rather than during the initiation 
of the process. Therefore, it would be interesting to investigate the effects of CORT treatment on 
atherosclerotic plaque development in a model where the development would be initiated earlier 
in life and the CORT treatment would take place at a later stage in plaque development. It must be, 
however, considered that the processes triggering the development of atherosclerosis in mice can 
be crucially different from humans, in which it is thought to be a complication of dyslipidemia in 
combination with insulin resistance. Thus the timing of the GC excess should be critically applied 
in the investigation of the relationship between the developent of atherosclerosis and dyslipidemia 
and insulin resistance. Since E3L.CETP on a cholesterol-rich diet become hyperlipidemic without 
developing insulin resistance, the mouse model could be further improved i.e. by adjusting the 
fat content of the diet. Finally, it is possible that the immunosuppressive potency of cortisol is not 
exactly the same as that of CORT, precluding perfect comparisons.
GCs have potent immunomodulatory properties, and synthetic GCs are widely used in 
the treatment of auto-immune diseases, like rheumatoid arthritis and inflammatory bowel 
disease. Conversely, inflammatory cytokines like TNF-alpha (TNF-α) and interleukin-6 (IL-6), can 
modulate pituitary hormone secretion, in particular ACTH secretion (79). This implicates that 
the neuroendocrine (central nervous system and hormones) and immune systems communicate 
bi-directionally. Recent data also showed that receptors belonging to the native immune system, 
the toll-like receptors (TLR), are stimulated by fat containing substances. Fatty acids are able to do 




















This moiety is a high affinity ligand for TLR4. Stimulation of these TLRs with saturated fatty acids 
appeared to evoke a pro-inflammatory response, that eventually resulted in insulin resistance and 
atherosclerosis (80). In agreement, a population-based study recently reported increased TLR type 
2 and -4 expression and activity in the monocytes of patients with MetS, but without diabetes or 
CVD, vs controls (81). This novel observation in the human clearly indicates that indeed increased 
TLR activity could contribute to an increased risk for diabetes and cardiovascular disease. Thus, 
the purpose for the bi-directional communication between the neuroendocrine (central nervous 
system and hormones) and immune systems is evident from an evolutionary point of view: it is 
crucial for survival to have an integrated system that informs the individual about threats, but also 
about opportunities. As a consequence, nutritional status and infectious pressure are integrated 
and lead to autonomous decisions to fight or flight, on reproduction or ageing, and on sleep or 
vigilance. In case of HFD, apparently we can simulate a bacterial attack, and mislead the body with 
unnecessary reactions and undesired effects (82). 
To evaluate the effects, long lasting or otherwise, of HFD and/or CORT, on the functionality of 
the HPA axis more detailed than what has been described in chapters 3, 4 and 5, it is necessary that 
future studies evaluate, and control for, stress induction, recovery from it and behavioral changes 
which they may induce. This is imperative in order to understand the behavior and choices of the 
individual induced by the adaptation of the HPA axis. Based on this knowledge, advice can be given 
to counteract the metabolic and psychological pathologies, which may help the individual to cope 
better and recover faster even in the presence of altered set points of hormone production and 
tissue sensitivity.
implications and future perspectives 
chapters 2 and 3 described in this thesis clearly demonstrate that studies with the aim to evaluate 
the effects of an intervention on the HPA axis have to fulfill certain methodological criteria to enable 
a reliable evaluation. Although such a statement seems obvious, our studies indicate that this was 
clearly not evident to researchers involved in metabolic studies and illustrates that the metabolic 
and behavioural effects of the stress response cannot be easily separated. Thus, such an appropriate 
design should, at least, take the following factors into account: choice of mouse strain, duration 
and content of the diet, standardization of housing conditions with a possibility to acclimate in 
advance and methods for stress-free sampling of CORT, and the timing of the sampling. This 
standardization and correction for parameters, which might otherwise hamper the interpretation 
of the results, is of importance since measures of the circulating plasma CORT only might not be 
sufficient enough when evaluating HPA axis activity since secondary effects might mask the “true” 
effects. This is the case in human obesity where increased cortisol levels are not present, whereas 
cortisol secretion is increased, primarily because of increased clearance and increased distribution 
volume of the circulating cortisol resulting in secondary central activation of the HPA axis (10, 11). 
In the same lines, diurnal CORT levels may reflect counteracting mechanisms directed towards 
regaining homeostasis both centrally and peripherally (18, 19-23). 
As we showed in chapter 3, HFD alone is able to modulate basal HPA axis activity and CORT 
metabolism in the central nervous system and in peripheral tissues. This might be the case also 
in the presence of a period of increased GCs (chapter 4), and could affect metabolic recovery 
and cardiovascular risk. Thus, it would be of interest to further elucidate the contribution of 
various diets during regular treatment of patients with CS, both before and after remission, to 
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metabolic abnormalities and behavior. These observations then could serve as a framework for 
guidelines for referral of patients who are prescribed steroid for (preventive) dietary advice. The 
profound inhibitory effect of high CORT on atherosclerotic plaque formation found in chapter 5 
was remarkable. Increased CORT exposure in mice with human-like lipoprotein metabolism had 
beneficial, long-lasting effects on atherosclerosis, but negatively affected body fat distribution and 
insulin sensitivity, by promoting fat accumulation in the long-term. This indicates that the increased 
atherosclerosis observed in humans in states of GC excess may not be related to cortisol per se, 
but may be the result of complex and perhaps indirect, effects of cortisol on the cardiovascular 
system. Given the widespread distribution of GCs and their immunosuppressive indications, these 
complex effects that include the effects on the endothelium and coagulation, apparently outweigh 
the immunosuppressive effects on plaque formation and merit further research.
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In de huidige westerse maatschappij die gekenmerkt wordt door weinig lichaamsbeweging en 
fastfood, komen overgewicht, type 2 diabetes (T2D) en hart-en vaatziekten en de complicaties 
daarvan steeds vaker voor. Tegelijkertijd is de waargenomen maatschappelijke stress factor door 
de 24-uurseconomie erg toegenomen. Er wordt gepostuleerd dat chronische stress, of dit nu 
maatschappelijk, sociaal, of door welke andere oorzaak dan ook, leidt tot dysfunctie van de 
hypothalamus-hypofyse-bijnier (HPA) as en dat dit betrokken is bij de ontwikkeling van het metabool 
syndroom. Een duidelijk voorbeeld hiervan zijn patiënten met het syndroom van Cushing die veel 
kenmerken hebben van het metabool syndroom en ook veel manifestaties hebben van hart-en 
vaatziekten. Het is echter onduidelijk wat de effecten zijn van (de ontwikkeling van) het metabool 
syndroom op de activiteit van de HPA as, en anderszins, wat de effecten zijn van overmatige 
blootstelling aan cortisol op het metabolisme. De geïnduceerde metabole veranderingen zoals 
deze gezien worden bij patiënten met het syndroom van Cushing zijn overduidelijk, maar zijn heel 
moeilijk te evalueren bij de mens. 
Het eerste deel van het proefschrift beschrijft in specifieke muizenmodellen de effecten 
van het vetgehalte in het dieet op de basale, dus niet gestimuleerde, activiteit van de HPA as, 
daar gesuggereerd is in de literatuur dat dit betrokken is in de pathofysiologie van het Metabool 
syndroom. In hoofdstuk 2 is een systematische review verricht gebruik makende van de belangrijkste 
elektronische databases, te weten: PubMed, EMBASE, Web of Science, the Cochrane database, en 
Science Direct. De primaire onderzoeksvraag was het effect te evalueren van studies die in muizen 
hebben gekeken naar de effecten van een hoog vetdieet op de activiteit van de hypothalamus-
hypofyse-bijnier-as. We includeerden alleen originele muizenstudies die parameters van de 
hypothalamus-hypofyse-bijnier-as beschreven na hoog vet dieet, en daarbij minstens een basale 
corticosteron spiegel vermelden met een adequate controle groep. Studies die gebruik maakten 
van muizen na adrenalectomie, alleen transgene muizen, een hoog vet dieet voor minder dan 2 
weken, of behalve een hoog vet dieet ook andere interventies rapporteerden, werden geëxcludeerd. 
Alle studies werden beoordeeld door twee onderzoekers. We vonden twintig studies die voldeden 
aan de inclusie criteria, waarbij echter de evaluatie van de hypothalamus-hypofyse-bijnier-as de 
primaire onderzoeksvraag was in slechts 5 van deze studies. De plasma corticosteron concentraties 
na dietaire interventie waren onveranderd in 40%, verhoogd in 30%, en verlaagd in 20% van de 
studies. Ook de effecten in de perifere weefsels en in het centrale zenuwstelsel waren niet consistent 
en werden slechts onderzocht in een klein aantal studies. Er waren echter tussen de studies grote 
verschillen in de gebruikte muizenstammen, experimentele condities, en de samenstelling en 
duur van het dieet. Uit deze studie komt dus duidelijk naar voren dat gegevens over de effecten 
van hoog vet dieet op de basale activiteit van de hypothalamus-hypofyse-bijnier-as in muizen 
beperkt zijn en niet-conclusief. Verschillen in experimentele condities maken een betrouwbare 
vergelijking erg moeilijk en benadrukken de noodzaak van gestandaardiseerde evaluaties om een 
betrouwbare evaluatie van de effecten van dieet geïnduceerde obesitas op de activiteit van de 
hypothalamus-hypofyse-bijnier-as mogelijk te maken. Daarom is het absoluut noodzakelijk de 
studie design hierop af te stemmen en moet tevens ook nog rekening worden gehouden met de 
volgende factoren: de keuze voor een specifieke muismodel (welke genetische achtergrond), 
de duur- en de samenstelling van het dieet, en standaardisatie van de huisvesting van de diertjes 
met de mogelijkheid om voor de start van het experiment te kunnen wennen aan de nieuwe 
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omgeving. Tot slot moeten ook methoden toegepast worden die het mogelijk maken om ‘stress 
vrij’ bloedmonsters af te kunnen nemen (de zgn sampling voor bepaling van corticosteron en/of 
ACTH) en moet ook rekening worden gehouden met het tijdstip van sampling.
In hoofdstuk 3 hebben we de in hoofdstuk 2 voorgestelde studie design toegepast met als 
doel de basale, dus niet gestreste, activiteit van de hypothalamus-hypofyse-bijnier-as te bestuderen 
in muizen tijdens de ontwikkeling van obesitas. De ontwikkeling van veel voorkomende kenmerken 
van het metabool syndroom, zoals insuline resistentie en obesitas kunnen gemakkelijk gestimuleerd 
worden met behulp van hoog-vet dieet in diermodellen van dieet geïnduceerde obesitas (DIO). 
In deze studie kregen mannelijke C57Bl/6J muizen een hoog- of laagvet dieet voor een periode 
van 12 weken waarbij de activiteit van HPA-as gemeten werd door middel van bepaling van de 
plasma corticosteron concentraties op een aantal vaste tijdstippen van de dag (om 07.00, 12.00, 
en om 18.00 h) elke twee weken. Daarnaast werd in het centrale zenuwstelsel de activiteit van de 
hypothalamus-hypofyse-bijnier-as aan het einde van het experiment gemeten aan de hand van de 
mRNA expressie van corticotropine-releasing hormone (CRH) en glucocorticoïd receptor (GR) in 
de hippocampus, de amygdala, en in de hypothalamus, alsook in de perifere weefsels middels de 
expressie van 11β-hydroxysteroid dehydrogenase type-1 en -2 (11β-HSD-1 en -2) in vetweefsel en 
in de lever. Binnen 1 week na start van het HFD was het lichaamsgewicht al significant hoger dan in 
de controle groep, hetgeen gepaard ging met significant lagere corticosteron concentraties om 
12.00 en 18.00 uur. Deze verlaagde waarden persisteerden gedurende de hele periode van 12 weken. 
Aan het einde van het experiment (na 12 weken HFD) werden ook veranderingen waargenomen in 
de centrale aansturing van de HPA as: de expressie van CRH mRNA in de PVN en amygdala en GR 
mRNA in de PVN was om 9.00 uur verlaagd, terwijl deze om 18.00 uur in de PVN en amygdala juist 
verhoogd was, alsook de GR mRNA expressie in een deel van de hippocampus (de CA1 regio). De 
11β-HSD-1 expressie in het vetweefsel was om 9.00 en 18.00 uur verlaagd zowel in het gonadale-, 
viscerale- en subcutane vet, terwijl de hepatische 11β-HSD-1 expression om 18.00 uur verhoogd 
was, zonder detecteerbare veranderingen in 11β-HSD-2 expressie. Dus door het toepassen van 
een gestandardiseerde, zgn “stress free” study design, is het mogelijk om de werkelijke effecten 
van een simpele interventie zoals een HFD op de basale activiteit van de hypothalamus-hypofyse-
bijnier-as te onderzoeken. Deze studie toont aan dat HFD complexe veranderingen induceert in de 
diurnale regulatie van de verschillende componenten van de hypothalamus-hypofyse-bijnier-as. 
Deze veranderingen worden niet overwegend gekenmerkt door verhoogde, maar juist door een 
verlaagde activiteit van de HPA as, die zeer waarschijnlijk adaptieve varanderingen weerspiegelen.
Het tweede gedeelte van het proefschrift richtte zich op de effecten van glucocorticoiden 
op het metabolisme. Het referentiekader hiervoor zijn waarnemingen bij patienten met het 
syndroom van Cushing, waar blootstelling aan cortisol excess, is geassocieerd met kenmerken van 
het metabool syndroom (MetS), zoals insuline resistentie, abnormale vet distributie en dyslipidemia 
en hart- en vaatziekten. Deze veranderingen blijken gegeven recentelijk onderzoek te persisteren 
zelfs als patienten al langdurig in remissie zijn na correctie van het cortisol excess. Bovendien is de 
rol van glucocorticoiden in de ontwikkeling van atherosclerosis nog niet duidelijk. Humane studies 
laten een duidelijke associatie zien tussen glucocorticoïd excess en hart- en vaatziekten; maar de 
meeste diermodellen wijzen op een remmend effects van glucocorticoïden op de ontwikkeling 
van atherosclerose. Echter, deze diermodellen weerspiegelen noch de lange-termijn effecten 

















In hoofdstuk 4 hebben we de effecten onderzocht van een periode van glucocorticoid excess 
op insuline gevoeligheid en lichaamssamenstelling. Het doel was om factoren te identificeren die 
het metabole herstel na een periode van glucocorticoid excess moduleren. Voor dit onderzoek 
gebruikten we mannelijke C57Bl/6J muizen, die dan wel een hoog- (HFD) of laag vetdieet (LFD) 
gevoerd werden, en daarnaast corticosteron (CORT) (50µg/ml) of vehicle kregen dat toegevoegd 
werd aan het drinkwater voor 4 weken, gevolgd door een ‘washout’ periode van 8 weken. 
Bloedmonsters voor de bepaling van circadiane plasma spiegels van corticosteron, lipiden, 
insuline, en glucose werden op reguliere tijdsintervallen afgenomen. De insulinegevoeligheid 
werd bepaald met behulp van een hyperinsulinemische-euglycemische clamp en lean body- 
en vetmassa werd geanalyseerd na 12 weken. We vonden dat de toevoeging van corticosteron 
aan het drinkwater resulteerde in verhoogde plasma corticosteron concentraties, alsook in een 
verhoogde voedselinname en verhoogde plasma insuline en lipiden concentraties. Het stoppen van 
de toevoeging van corticosteron aan het drinkwater normaliseerde de corticosteron concentraties, 
de voedselinname en het lichaamsgewicht. Acht weken na staken van de corticosteron toediening 
waren de insuline concentraties nog steeds significant hoger met beide dieten dan in het controle 
experiment en was bij corticosteron behandelde muizen op HFD tevens nog steeds sprake van 
persisterende verminderde lean body mass en een hogere vetmassa. Het lijkt er dus op dat een 
periode van corticosteron excess langdurige metabole veranderingen induceert, waarbij de 
veranderingen in lichaamssamenstelling alleen optreden in aanwezigheid van een HFD. Deze 
observaties wijzen op dieet-afhankelijke effecten van corticosteron die mogelijk bij zouden kunnen 
dragen aan het persisterende afwijkende cardiovasculaire risicoprofiel zoals gezien wordt bij 
patienten behandeld voor het syndroom van Cushing, en mogelijk dan ook bij individuen die 
bloot staan aan chronische stress. In hoofdstuk 5 zijn de effecten van glucocorticoidexcess, 
zowel passagėre als continue toediening, onderzocht op de ontwikkeling van atherosclerose 
in een specifiek muismodel met een lipoproteine metabolism die vergelijkbaar is met die bij 
de mens, namelijk vrouwelijke APOE*3-Leiden.CETP (E3L.CETP) muizen, en die atherosclerose 
ontwikkelen na blootstelling aan een zgn ‘Western-type’ diet. Een dergelijk Western-type dieet 
bevatte voor dit experiment 0.1% cholesterol en duurde 20 weken. Na 3 weken werden de muizen 
gematched voor leeftijd, plasma cholesterol concentraties, trigylceriden en phospholipiden alsook 
lichaamsgewicht, en kregen ze corticosteron (50 µg/ml) in het drinkwater voor of 5 weken (transient 
groep) of 17 weken (continue groep), of ze kregen alleen drinkwater zonder corticosteron (controle 
groep). Aan het einde van de studie, werd de ernst van atherosclerose en de grootte van de 
atherosclerotische plaque gemeten in de aortaboog. Tevens werd het aantal monocyten aan het 
endotheel vastgelegd alsook het aantal macrofagen in de plaque. We vonden dat corticosterone 
behandeling het lichaamsgewicht en voedselinname verhoogde voor de gehele duur van de 
behandeling en op de lange-termijn de vetmassa verhoogde in beide behandelgroepen. Zowel in 
de ‘transient’ als in de ‘continue’ groep verlaagde corticosteron behandeling het totale oppervlakte 
van de atherosclerotische lesie in dezelfde mate blijkbaar onafhankelijk van het cholesterol daar 
de plasma cholesterol concentraties niet lager werden. Na continue behandeling werd tevens 
een reductie van het aantal macrofagen in de plaque gevonden en eenzelfde trend was aanwezig 
na ‘transient’ behandeling. Hieruit kunnen we concluderen dat sterk verhoogde blootstelling aan 
corticosteron in muizen met een humaan lipoproteine metabolisme gunstige en langdurige effecten 
heeft op atherosclerose, maar negatief de vetdistributie en insuline gevoeligheid beinvloedt, 
door vetstapeling te fasciliteren op de langetermijn. Dit betekent dat de sterke associatie tussen 
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atherosclerose en glucocorticoid excess zoals geobserveerd wordt bij de mens mogelijk niet 
gerelateerd zijn aan cortisol per se, maar het resultaat kunnen zijn van complex effecten van cortisol 
op het endotheel en/of op de stollingsactivatie.
Samenvattend dragen deze studies bij aan het begrijpen van de rol van de hypothalamus-
hypofyse-bijnier-as en glucocorticoiden in de pathofysiologie van het metabool syndroom, maar 
illustreren ook dat er effecten zijn van dieet geinduceerde obesitas op de hypothalamus-hypofyse-
bijnier-as. De studies in dit proefschrift laten duidelijk zien dat voor een betrouwbare evaluatie 
van de hypothalamus-hypofyse-bijnier-as, een geschikte studie design een absolute voorwaarde 
is. Dan wordt zichtbaar dat een hoog vet gehalte in het dieet de activiteit van de hypothalamus-
hypofyse-bijnier-as onderdrukt, hetgeen waarschijnlijk een adaptatie is om de dieet-geinduceerde 
ontwikkeling van insuline resistentie en obesitas tegen te gaan, niet alleen in perifere weefsels maar 
ook in het central zenuwstelsel. Bovendien tonen we in dit proefschrift aan dat een periodieke 
blootstelling aan hoge corticosteron spiegels langdurige gunstige effecten heeft op atherosclerose, 
maar tegelijkertijd negatief de lichaamssamenstelling beinvloedt en, vetstapeling en insuline 
resistentie bevordert, hetgeen nog meer versterkt worden door een hoog- vet dieet. 
De in dit proefschrift gepresenteerde bevindingen zijn voor een breed publiek relevant: 
eenieder moet leren omgaan met een toenemend aantal hedendaagse dagelijkse stressoren, zoals 
sociale stress, slaapstoornissen, de consumptie van “comfort food” maar ook “emotional eating” 
dat de ontwikkeling van obesitas, het metabool syndroom, type 2 diabetes en hart- en vaatziekten 
fasciliteert. Bovendien geven enkele van deze bevindingen klinische relevante aanknopingspunten 
voor artsen en patienten als steroiden voorgeschreven dienen te worden voor uiteenlopende 
indicaties, daar een preventief dietetair advies bij zou kunnen dragen aan verbetering van het 
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